false2024Q3000163156912/31oneseven years, three monthshttp://fasb.org/us-gaap/2024#OtherAssetshttp://fasb.org/us-gaap/2024#OtherAssetshttp://fasb.org/us-gaap/2024#OtherLiabilitieshttp://fasb.org/us-gaap/2024#OtherLiabilitieshttp://fasb.org/us-gaap/2024#InterestExpenseNonoperatinghttp://fasb.org/us-gaap/2024#InterestExpenseNonoperatinghttp://fasb.org/us-gaap/2024#InterestExpenseNonoperatinghttp://fasb.org/us-gaap/2024#InterestExpenseNonoperatingP3YP3Y333333http://fasb.org/us-gaap/2024#OtherAssetshttp://fasb.org/us-gaap/2024#OtherAssetshttp://fasb.org/us-gaap/2024#OtherLiabilitieshttp://fasb.org/us-gaap/2024#OtherLiabilitieshttp://fasb.org/us-gaap/2024#OtherLiabilitieshttp://fasb.org/us-gaap/2024#OtherLiabilitiesxbrli:sharesiso4217:USDiso4217:USDxbrli:shareschct:realEstatePropertychct:stateutr:sqftxbrli:purechct:segmentchct:leasechct:transactionchct:optionchct:derivative_instrumentchct:hospitalchct:project00016315692024-01-012024-09-3000016315692024-10-2200016315692024-09-3000016315692023-12-3100016315692024-07-012024-09-3000016315692023-07-012023-09-3000016315692023-01-012023-09-3000016315692023-01-012023-03-310001631569us-gaap:PreferredStockMember2024-06-300001631569us-gaap:CommonStockMember2024-06-300001631569us-gaap:AdditionalPaidInCapitalMember2024-06-300001631569chct:CumulativeNetIncomeDeficitMember2024-06-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001631569chct:CumulativeDividendsMember2024-06-3000016315692024-06-300001631569us-gaap:CommonStockMember2024-07-012024-09-300001631569us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001631569chct:CumulativeNetIncomeDeficitMember2024-07-012024-09-300001631569chct:CumulativeDividendsMember2024-07-012024-09-300001631569us-gaap:PreferredStockMember2024-09-300001631569us-gaap:CommonStockMember2024-09-300001631569us-gaap:AdditionalPaidInCapitalMember2024-09-300001631569chct:CumulativeNetIncomeDeficitMember2024-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001631569chct:CumulativeDividendsMember2024-09-300001631569us-gaap:PreferredStockMember2023-12-310001631569us-gaap:CommonStockMember2023-12-310001631569us-gaap:AdditionalPaidInCapitalMember2023-12-310001631569chct:CumulativeNetIncomeDeficitMember2023-12-310001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001631569chct:CumulativeDividendsMember2023-12-310001631569us-gaap:CommonStockMember2024-01-012024-09-300001631569us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001631569chct:CumulativeNetIncomeDeficitMember2024-01-012024-09-300001631569chct:CumulativeDividendsMember2024-01-012024-09-300001631569us-gaap:PreferredStockMember2023-06-300001631569us-gaap:CommonStockMember2023-06-300001631569us-gaap:AdditionalPaidInCapitalMember2023-06-300001631569chct:CumulativeNetIncomeDeficitMember2023-06-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001631569chct:CumulativeDividendsMember2023-06-3000016315692023-06-300001631569us-gaap:CommonStockMember2023-07-012023-09-300001631569us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001631569chct:CumulativeNetIncomeDeficitMember2023-07-012023-09-300001631569chct:CumulativeDividendsMember2023-07-012023-09-300001631569us-gaap:PreferredStockMember2023-09-300001631569us-gaap:CommonStockMember2023-09-300001631569us-gaap:AdditionalPaidInCapitalMember2023-09-300001631569chct:CumulativeNetIncomeDeficitMember2023-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001631569chct:CumulativeDividendsMember2023-09-3000016315692023-09-300001631569us-gaap:PreferredStockMember2022-12-310001631569us-gaap:CommonStockMember2022-12-310001631569us-gaap:AdditionalPaidInCapitalMember2022-12-310001631569chct:CumulativeNetIncomeDeficitMember2022-12-310001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001631569chct:CumulativeDividendsMember2022-12-3100016315692022-12-310001631569us-gaap:CommonStockMember2023-01-012023-09-300001631569us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001631569chct:CumulativeNetIncomeDeficitMember2023-01-012023-09-300001631569chct:CumulativeDividendsMember2023-01-012023-09-300001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-09-300001631569chct:MedicalOfficeBuildingMember2024-09-300001631569chct:InpatientRehabilitationHospitalMember2024-09-300001631569chct:AcuteInpatientBehavioralMember2024-09-300001631569chct:SpecialtyCentersMember2024-09-300001631569chct:PhysicianClinicsMember2024-09-300001631569chct:SurgicalCentersandHospitalsMember2024-09-300001631569chct:BehavioralFacilitiesMember2024-09-300001631569chct:LongTermAcuteCareFacilityMember2024-09-300001631569stpr:TX2024-09-300001631569stpr:IL2024-09-300001631569stpr:OH2024-09-300001631569stpr:FL2024-09-300001631569stpr:PA2024-09-300001631569chct:OtherStatesMember2024-09-300001631569chct:LifePointHealthMember2024-09-300001631569chct:USHealthVestMember2024-09-300001631569chct:OtherTenantMember2024-09-300001631569chct:ElevenRealEstatePropertyMember2024-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32024Member2024-07-012024-09-300001631569chct:AcquisitionsOfPropertiesDuringQ22024Member2024-04-012024-06-300001631569chct:AcquisitionsOfPropertiesDuringQ22024Member2024-01-012024-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12024Member2024-01-012024-03-310001631569chct:AcquisitionsOfPropertiesDuringQ12024Member2024-01-012024-09-300001631569chct:NewBedfordMAMemberchct:AcquisitionsOfPropertiesDuringQ12024Member2024-01-012024-09-300001631569chct:NewBedfordMAMemberchct:AcquisitionsOfPropertiesDuringQ12024Member2024-09-300001631569chct:ElktonMDMemberchct:AcquisitionsOfPropertiesDuringQ12024Member2024-01-012024-09-300001631569chct:ElktonMDMemberchct:AcquisitionsOfPropertiesDuringQ12024Member2024-09-300001631569chct:BemidjiMNMemberchct:AcquisitionsOfPropertiesDuringQ12024Member2024-01-012024-09-300001631569chct:BemidjiMNMemberchct:AcquisitionsOfPropertiesDuringQ12024Member2024-09-300001631569chct:SanAntonioTXMemberchct:AcquisitionsOfPropertiesDuringQ22024Member2024-01-012024-09-300001631569chct:SanAntonioTXMemberchct:AcquisitionsOfPropertiesDuringQ22024Member2024-09-300001631569chct:CampHillPAMemberchct:AcquisitionsOfPropertiesDuringQ32024Member2024-01-012024-09-300001631569chct:CampHillPAMemberchct:AcquisitionsOfPropertiesDuringQ32024Member2024-09-300001631569chct:AcquisitionsOfPropertiesDuring2024Member2024-01-012024-09-300001631569chct:AcquisitionsOfPropertiesDuring2024Member2024-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2024-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMemberus-gaap:LandAndLandImprovementsMember2024-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMemberus-gaap:BuildingAndBuildingImprovementsMember2024-09-300001631569us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2024-09-300001631569us-gaap:AboveMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2024-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2024-01-012024-09-300001631569us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchct:SurgicalCenterMember2024-09-300001631569us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberchct:SurgicalCenterMember2024-07-012024-09-300001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:LandMember2024-09-300001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:LandMember2023-12-310001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberchct:BuildingsImprovementsAndLeaseholdsMember2024-09-300001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberchct:BuildingsImprovementsAndLeaseholdsMember2023-12-310001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:RealEstateMember2024-09-300001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:RealEstateMember2023-12-310001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMemberchct:TermLoanMember2024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMemberchct:TermLoanMember2023-12-310001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMemberchct:TermLoanMember2024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMemberchct:TermLoanMember2023-12-310001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMemberchct:TermLoanMember2024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMemberchct:TermLoanMember2023-12-310001631569us-gaap:MortgagesMember2024-09-300001631569us-gaap:MortgagesMember2023-12-310001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMemberus-gaap:LineOfCreditMember2024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMemberchct:TermLoanMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMemberchct:TermLoanMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:CreditFacilityAccordionFeatureMember2024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MinimumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MaximumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:RevolvingCreditFacilityUnusedBorrowingCapacityRate1Memberus-gaap:LineOfCreditMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:RevolvingCreditFacilityUnusedBorrowingCapacityRate2Memberus-gaap:LineOfCreditMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMemberchct:SimpleSecuredOvernightFinancingRateSOFRRateMembersrt:MaximumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMemberus-gaap:BaseRateMembersrt:MinimumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMemberus-gaap:BaseRateMembersrt:MaximumMember2024-01-012024-09-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMember2024-09-300001631569us-gaap:MortgagesMember2024-06-300001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMemberchct:TermLoanMember2024-01-012024-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-09-300001631569us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001631569us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-07-012024-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2023-07-012023-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-01-012024-09-300001631569us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2023-01-012023-09-3000016315692023-01-012023-12-310001631569us-gaap:CommonStockMemberchct:AtTheMarketOfferingProgramMember2024-01-012024-09-300001631569us-gaap:CommonStockMemberchct:AtTheMarketOfferingProgramMember2024-09-300001631569us-gaap:CommonStockMemberchct:AtTheMarketOfferingProgramMember2024-07-012024-09-300001631569chct:A2024IncentivePlanMember2024-05-020001631569us-gaap:RestrictedStockMember2024-06-300001631569us-gaap:RestrictedStockMember2023-06-300001631569us-gaap:RestrictedStockMember2023-12-310001631569us-gaap:RestrictedStockMember2022-12-310001631569chct:RestrictedCommonStockStockinLieuofCompensationMember2024-07-012024-09-300001631569chct:RestrictedCommonStockStockinLieuofCompensationMember2023-07-012023-09-300001631569chct:RestrictedCommonStockStockinLieuofCompensationMember2024-01-012024-09-300001631569chct:RestrictedCommonStockStockinLieuofCompensationMember2023-01-012023-09-300001631569chct:RestrictedCommonStockStockAwardsMember2024-07-012024-09-300001631569chct:RestrictedCommonStockStockAwardsMember2023-07-012023-09-300001631569chct:RestrictedCommonStockStockAwardsMember2024-01-012024-09-300001631569chct:RestrictedCommonStockStockAwardsMember2023-01-012023-09-300001631569us-gaap:RestrictedStockMember2024-07-012024-09-300001631569us-gaap:RestrictedStockMember2023-07-012023-09-300001631569us-gaap:RestrictedStockMember2024-01-012024-09-300001631569us-gaap:RestrictedStockMember2023-01-012023-09-300001631569us-gaap:RestrictedStockMember2024-09-300001631569us-gaap:RestrictedStockMember2023-09-300001631569us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-01-122024-01-120001631569us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:RestrictedStockMembersrt:MinimumMember2024-01-122024-01-120001631569us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:RestrictedStockMembersrt:MaximumMember2024-01-122024-01-120001631569chct:RestrictedCommonStockStockinLieuofCompensationMemberchct:A2014IncentivePlanMember2024-01-122024-01-120001631569chct:RestrictedCommonStockStockInLieuOfCompensationRestrictedPeriodMemberchct:A2014IncentivePlanMember2024-01-122024-01-120001631569us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-01-122024-01-120001631569us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-05-022024-05-020001631569us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-05-162024-05-160001631569chct:RestrictedCommonStockStockinLieuofCompensationMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-05-162024-05-160001631569chct:RestrictedCommonStockStockInLieuOfCompensationRestrictedPeriodMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-05-162024-05-160001631569us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-06-032024-06-030001631569us-gaap:ShareBasedPaymentArrangementEmployeeMemberchct:A2024IncentivePlanMemberus-gaap:RestrictedStockMember2024-07-012024-09-300001631569us-gaap:ShareBasedPaymentArrangementEmployeeMemberchct:A2024IncentivePlanMemberus-gaap:RestrictedStockMembersrt:MinimumMember2024-07-012024-09-300001631569us-gaap:ShareBasedPaymentArrangementEmployeeMemberchct:A2024IncentivePlanMemberus-gaap:RestrictedStockMembersrt:MaximumMember2024-07-012024-09-300001631569chct:RestrictedCommonStockStockinLieuofCompensationMemberchct:A2024IncentivePlanMember2024-07-012024-09-300001631569chct:RestrictedCommonStockStockInLieuOfCompensationRestrictedPeriodMemberchct:A2024IncentivePlanMember2024-07-012024-09-300001631569chct:A2024IncentivePlanMember2024-01-020001631569chct:A2014IncentivePlanMember2024-01-010001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2024-01-012024-03-310001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014IncentivePlanMember2024-01-022024-01-020001631569chct:A2014IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMembersrt:ExecutiveOfficerMember2024-01-022024-01-020001631569chct:A2014IncentivePlanMemberchct:AbsoluteTSRUnitsMembersrt:ExecutiveOfficerMember2024-01-022024-01-020001631569chct:A2014IncentivePlanMemberchct:RelativeTSRUnitsMembersrt:ExecutiveOfficerMember2024-01-022024-01-020001631569chct:A2014IncentivePlanMemberchct:TimeBasedTSRUnitsMembersrt:ExecutiveOfficerMember2024-01-022024-01-020001631569chct:PerformanceBasedRestrictedStockUnitsMemberchct:A2014IncentivePlanMember2024-01-022024-01-020001631569chct:PerformanceBasedRestrictedStockUnitsMemberchct:A2014IncentivePlanMember2024-01-020001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2024IncentivePlanMember2024-06-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014IncentivePlanMember2023-06-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014And2024IncentivePlanMember2023-12-310001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014IncentivePlanMember2022-12-310001631569chct:AbsoluteTSRUnitsMemberchct:A2024IncentivePlanMember2024-07-012024-09-300001631569chct:AbsoluteTSRUnitsMemberchct:A2014IncentivePlanMember2023-07-012023-09-300001631569chct:AbsoluteTSRUnitsMemberchct:A2014And2024IncentivePlanMember2024-01-012024-09-300001631569chct:AbsoluteTSRUnitsMemberchct:A2014IncentivePlanMember2023-01-012023-09-300001631569chct:RelativeTSRUnitsMemberchct:A2024IncentivePlanMember2024-07-012024-09-300001631569chct:RelativeTSRUnitsMemberchct:A2014IncentivePlanMember2023-07-012023-09-300001631569chct:RelativeTSRUnitsMemberchct:A2014And2024IncentivePlanMember2024-01-012024-09-300001631569chct:RelativeTSRUnitsMemberchct:A2014IncentivePlanMember2023-01-012023-09-300001631569chct:TimeBasedTSRUnitsMemberchct:A2024IncentivePlanMember2024-07-012024-09-300001631569chct:TimeBasedTSRUnitsMemberchct:A2014IncentivePlanMember2023-07-012023-09-300001631569chct:TimeBasedTSRUnitsMemberchct:A2014And2024IncentivePlanMember2024-01-012024-09-300001631569chct:TimeBasedTSRUnitsMemberchct:A2014IncentivePlanMember2023-01-012023-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2024IncentivePlanMember2024-07-012024-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014IncentivePlanMember2023-07-012023-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014And2024IncentivePlanMember2024-01-012024-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014IncentivePlanMember2023-01-012023-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2024IncentivePlanMember2024-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014IncentivePlanMember2023-09-300001631569us-gaap:RestrictedStockUnitsRSUMemberchct:A2014And2024IncentivePlanMember2024-09-300001631569chct:TimeBasedTSRUnitsMemberchct:A2014IncentivePlanMember2024-07-012024-07-010001631569chct:A2014IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001631569chct:A2014IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001631569chct:A2014IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001631569us-gaap:NotesReceivableMemberchct:TermLoanMember2024-09-300001631569us-gaap:NotesReceivableMemberchct:TermLoanMember2023-12-310001631569chct:LongTermAcuteCareFacilityMemberchct:TermLoanMember2024-01-012024-09-300001631569chct:InpatientRehabilitationHospitalMemberchct:TermLoanMember2024-01-012024-09-300001631569us-gaap:NotesReceivableMemberchct:TermLoanMember2024-01-012024-09-300001631569chct:NoteReceivable4Memberchct:TermLoanMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310001631569chct:NoteReceivable4Memberchct:TermLoanMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-09-300001631569chct:NoteReceivable4Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberus-gaap:RevolvingCreditFacilityMember2024-09-300001631569chct:NoteReceivable4Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberus-gaap:RevolvingCreditFacilityMember2023-12-310001631569chct:GeriatricBehavioralHospitalMember2024-01-012024-09-300001631569chct:NoteReceivable2Memberus-gaap:UnfundedLoanCommitmentMember2024-09-300001631569chct:NoteReceivable3Memberus-gaap:UnfundedLoanCommitmentMember2024-09-300001631569us-gaap:NotesReceivableMember2024-01-012024-09-300001631569us-gaap:NotesReceivableMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300001631569us-gaap:NotesReceivableMember2024-09-300001631569chct:GeriatricInpatientBehavioralHospitalMemberus-gaap:NotesReceivableMember2024-06-300001631569us-gaap:NotesReceivableMember2024-06-300001631569chct:NoteReceivable2Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-09-300001631569chct:NoteReceivable2Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310001631569us-gaap:NotesReceivableMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMember2024-11-012024-12-310001631569chct:NoteReceivable2Memberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300001631569chct:NoteReceivable2Memberus-gaap:RevolvingCreditFacilityMember2024-09-300001631569chct:NoteReceivable5Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-09-300001631569chct:NoteReceivable5Member2024-01-012024-09-300001631569chct:NoteReceivable1Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-09-300001631569chct:NoteReceivable3Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-09-300001631569us-gaap:NotesReceivableMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001631569us-gaap:FairValueInputsLevel2Memberus-gaap:NotesReceivableMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001631569us-gaap:NotesReceivableMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001631569us-gaap:FairValueInputsLevel2Memberus-gaap:NotesReceivableMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001631569us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001631569us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001631569us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001631569us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001631569us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001631569us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001631569us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001631569us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001631569us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001631569chct:TenantImprovementsAllowancesMember2024-09-300001631569chct:RedevelopmentProjectsMember2024-01-012024-09-300001631569chct:RedevelopmentProjectsMember2024-09-300001631569chct:CapitalImprovementsMember2024-09-300001631569chct:CapitalImprovementsRedevelopmentProjectsMember2024-01-012024-09-300001631569chct:CapitalImprovementsRedevelopmentProjectsMember2024-09-300001631569us-gaap:SubsequentEventMember2024-10-242024-10-240001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2024-10-160001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2024-10-162024-10-160001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMemberchct:TermLoanMemberus-gaap:SubsequentEventMember2024-10-162024-10-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM             TO
Commission file number: 001-37401
Community Healthcare Trust Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Maryland
46-5212033
(State or Other Jurisdiction of Incorporation or Organization)
(I.R.S. Employer Identification No.)
3326 Aspen Grove Drive
Suite 150
Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)
(615) 771-3052
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading SymbolName of each exchange on which registered
Common stock, $0.01 par value per shareCHCTNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒     No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒     No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Emerging-growth company
☐
Non-accelerated filer
☐
Smaller reporting 
company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Yes  ☐     No ☒
The Registrant had 28,242,370 shares of Common Stock, $0.01 par value per share, outstanding as of October 22, 2024.
1

COMMUNITY HEALTHCARE TRUST INCORPORATED
FORM 10-Q
SEPTEMBER 30, 2024
TABLE OF CONTENTS
Page
        
2

PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars and shares in thousands, except per share amounts)
(Unaudited)
September 30, 2024December 31, 2023
ASSETS
Real estate properties
Land and land improvements
$146,118 $136,532 
Buildings, improvements, and lease intangibles
989,019 913,416 
Personal property
326 299 
Total real estate properties
1,135,463 1,050,247 
Less accumulated depreciation
(232,747)(200,810)
Total real estate properties, net
902,716 849,437 
Cash and cash equivalents
2,836 3,491 
Restricted cash
— 1,142 
Real estate properties held for sale6,351 7,466 
Other assets, net
69,876 83,876 
Total assets
$981,779 $945,412 
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
Debt, net
$473,716 $403,256 
Accounts payable and accrued liabilities
14,422 12,032 
Other liabilities, net
16,489 16,868 
Total liabilities
504,627 432,156 
Commitments and contingencies


Stockholders' Equity
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 450,000 shares authorized; 28,242 and 27,613 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
282 276 
Additional paid-in capital
702,014 688,156 
Cumulative net income
83,843 88,856 
Accumulated other comprehensive income
10,016 16,417 
Cumulative dividends
(319,003)(280,449)
Total stockholders’ equity
477,152 513,256 
Total liabilities and stockholders' equity
$981,779 $945,412 

See accompanying notes to the condensed consolidated financial statements.
3

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(Unaudited; Dollars and shares in thousands, except per share amounts)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
REVENUES
Rental income
$29,335 $27,690 $85,582 $80,582 
Other operating interest, net
304 1,045 906 3,139 
29,639 28,735 86,488 83,721 
EXPENSES
Property operating
5,986 5,456 17,349 15,115 
General and administrative (1)
4,935 3,618 14,249 23,610 
Depreciation and amortization
10,927 11,208 31,981 29,445 
21,848 20,282 63,579 68,170 
OTHER (EXPENSE) INCOME
Gain on sale (impairment) of depreciable real estate asset5 (102)(135)(102)
Interest expense
(6,253)(4,641)(17,301)(12,773)
Credit loss reserve
— — (11,000)— 
Deferred income tax expense
— (221)— (306)
Interest and other income, net
206 3 514 777 

(6,042)(4,961)(27,922)(12,404)
NET INCOME (LOSS)$1,749 $3,492 $(5,013)$3,147 
NET INCOME (LOSS) PER COMMON SHARE
Net income (loss) per common share - Basic$0.04 $0.11 $(0.27)$0.05 
Net income (loss) per common share - Diluted$0.04 $0.11 $(0.27)$0.05 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC
26,660 25,514 26,479 24,940 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED
26,660 25,514 26,479 24,940 
___________
(1) General and administrative expenses for the nine months ended September 30, 2024 included stock-based compensation expense totaling approximately $7.4 million. General and administrative expenses for the nine months ended September 30, 2023 included stock-based compensation expense totaling approximately $17.9 million, including the accelerated amortization of stock-based compensation totaling approximately $11.8 million recognized upon the passing of our former CEO and President in the first quarter of 2023. See Note 9 – Stock Incentive Plan.
See accompanying notes to the condensed consolidated financial statements.









4


COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(Unaudited; Dollars in thousands)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
NET INCOME (LOSS)$1,749 $3,492 $(5,013)$3,147 
Other comprehensive (loss) income:
(Decrease) increase in fair value of cash flow hedges(8,749)8,691 1,824 13,593 
Reclassification for amounts recognized as interest expense
(2,725)(2,738)(8,225)(7,222)
Total other comprehensive (loss) income(11,474)5,953 (6,401)6,371 
COMPREHENSIVE (LOSS) INCOME$(9,725)$9,445 $(11,414)$9,518 

See accompanying notes to the condensed consolidated financial statements.

5

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
(Unaudited; Dollars and shares in thousands, except per share amounts)
Preferred Stock
Common Stock
Additional Paid in Capital
Cumulative Net Income
Accumulated Other Comprehensive Income
Cumulative Dividends
Total Stockholders' Equity
Shares
Amount
Shares
Amount
Balance at June 30, 2024— $— 28,049$280 $699,833 $82,094 $21,490 $(305,926)$497,771 
Issuance of common stock, net of issuance costs— — — — (80)— — — (80)
Stock-based compensation, net of forfeitures— — 206 2 2,495 — — — 2,497 
Shares withheld on vesting of stock-based compensation— — (13)— (234)— — — (234)
Decrease in fair value of cash flow hedges— — —— — — (8,749)— (8,749)
Reclassification for amounts recognized as interest expense— — —— — — (2,725)— (2,725)
Net income— — —— — 1,749 — — 1,749 
Dividends to common stockholders ($0.4625 per share)
— — —— — — — (13,077)(13,077)
Balance at September 30, 2024— — 28,242 282 702,014 83,843 10,016 (319,003)477,152 
Balance at December 31, 2023— $— 27,613$276 $688,156 $88,856 $16,417 $(280,449)$513,256 
Issuance of common stock, net of issuance costs— — 3133 7,256 — — — 7,259 
Stock-based compensation, net of forfeitures— — 3503 7,387 — — — 7,390 
Shares withheld on vesting of stock-based compensation— — (34)— (785)— — — (785)
Increase in fair value of cash flow hedges— — —— — — 1,824 — 1,824 
Reclassification for amounts recognized as interest expense— — —— — — (8,225)— (8,225)
Net loss— — —— — (5,013)— — (5,013)
Dividends to common stockholders ($1.3800 per share)
— — —— — — — (38,554)(38,554)
Balance at September 30, 2024— $— 28,242$282 $702,014 $83,843 $10,016 $(319,003)$477,152 


See accompanying notes to the condensed consolidated financial statements.
6

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023
(Unaudited; Dollars and shares in thousands, except per share amounts)
Preferred Stock
Common Stock
Additional Paid in Capital
Cumulative Net Income
Accumulated Other Comprehensive Income
Cumulative Dividends
Total Stockholders' Equity
Shares
Amount
Shares
Amount
Balance at June 30, 2023— $— 26,541$265 $657,057 $80,797 $23,085 $(255,879)$505,325 
Issuance of common stock, net of issuance costs— — 5526 17,763 — — — 17,769 
Stock-based compensation, net of forfeitures— — 1722 1,896 — — — 1,898 
Increase in fair value of cash flow hedges— — —— — 8,691 — 8,691 
Reclassification for amounts recognized as interest expense— — —— — — (2,738)— (2,738)
Net income— — —— — 3,492 — — 3,492 
Dividends to common stockholders ($0.4525 per share)
— — —— — — — (12,143)(12,143)
Balance at September 30, 2023— $— 27,265$273 $676,716 $84,289 $29,038 $(268,022)$522,294 
Balance at December 31, 2022— $— 25,897$259 $625,136 $81,142 $22,667 $(232,390)$496,814 
Issuance of common stock— — 1,03711 34,610 — — — 34,621 
Stock-based compensation, net of forfeitures— — 3313 17,933 — — — 17,936 
Shares withheld on vesting of stock-based compensation— — —— (963)— — — (963)
Increase in fair value of cash flow hedges— — —— — 13,593 — 13,593 
Reclassification for amounts recognized as interest expense— — —— — — (7,222)— (7,222)
Net income— — —— — 3,147 — — 3,147 
Dividends to common stockholders ($1.3500 per share)
— — —— — — — (35,632)(35,632)
Balance at September 30, 2023— $— 27,265$273 $676,716 $84,289 $29,038 $(268,022)$522,294 


See accompanying notes to the condensed consolidated financial statements.
7

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited; Dollars in thousands)
Nine Months Ended
September 30,
20242023
OPERATING ACTIVITIES
Net (loss) income$(5,013)$3,147 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization
31,981 29,445 
Other amortization
636 558 
Stock-based compensation
7,390 6,137 
Accelerated amortization of stock-based compensation— 11,799 
Straight-line rent receivable
(1,230)(2,180)
Net gain from insurance recovery on casualty loss— (706)
Impairment of real estate asset, net of gain on sale135 102 
Credit loss reserve
11,000 — 
Deferred income tax expense— 306 
Changes in operating assets and liabilities:
Other assets
(3,543)(3,082)
Accounts payable and accrued liabilities
2,263 3,337 
Other liabilities
(402)(1,772)
Net cash provided by operating activities43,217 47,091 
INVESTING ACTIVITIES
Acquisitions of real estate
(64,152)(91,993)
        Proceeds from sale of real estate
965 — 
        Funding of notes receivable
(2,875)(1,985)
Proceeds from the repayment of notes receivable
2,370 3,045 
Insurance proceeds from casualty loss— 2,273 
Capital expenditures on existing real estate properties
(19,483)(11,461)
Net cash used in investing activities(83,175)(100,121)
FINANCING ACTIVITIES
Net borrowings on revolving credit facility75,000 48,000 
Mortgage note repayments
(4,820)(94)
Dividends paid
(38,554)(35,632)
Proceeds from issuance of common stock
7,492 34,766 
Taxes paid on behalf of employees and shares withheld upon shares vesting(785)(963)
Equity issuance costs
(172)(182)
Net cash provided by financing activities38,161 45,895 
Decrease in cash, cash equivalents and restricted cash(1,797)(7,135)
Cash, cash equivalents and restricted cash, beginning of period
4,633 12,068 
Cash, cash equivalents and restricted cash, end of period
$2,836 $4,933 
Supplemental Cash Flow Information:
Interest paid (net of capitalized interest)
$16,932 $9,868 
Invoices accrued for construction, tenant improvement, and other capitalized costs
$5,124 $4,922 
Reclassification of registration statement costs incurred in prior years to equity issuance costs
$269 $145 
Increase in fair value of cash flow hedges$1,824 $13,593 
Income taxes paid
$31 $90 
Capitalized interest$154 $514 
See accompanying notes to the condensed consolidated financial statements.
8

COMMUNITY HEALTHCARE TRUST INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2024
(Unaudited)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business Overview
Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of September 30, 2024, the Company had gross investments of approximately $1.1 billion in 198 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as an asset held for sale with a net investment totaling approximately $6.4 million. See Note 10 – Other Assets, net and Note 4 – Real Estate Acquisitions, Disposition, and Assets Held for Sale, respectively). The properties are located in 35 states, totaling approximately 4.4 million square feet in the aggregate and were approximately 91.3% leased, excluding the real estate asset held for sale, at September 30, 2024 with a weighted average remaining lease term of approximately 6.8 years. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm's review.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes, including among others, estimates related to impairment assessments, purchase price allocations, valuation of properties held for sale, allowances for accounts and interest receivables, and valuation of financial instruments. Actual results may materially differ from those estimates.

Cash and Cash Equivalents and Restricted Cash
Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash consisted of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Company's Condensed
9
Notes to Condensed Consolidated Financial Statements - Continued
Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows:
 Balance as of September 30,
(Dollars in thousands)20242023
Cash and cash equivalents$2,836 $3,885 
Restricted cash— 1,048 
Cash, cash equivalents and restricted cash$2,836 $4,933 

Rental Income
The primary source of revenue for the Company is generated through its leasing arrangements with its tenants which is accounted for under ASC Topic 842. The Company's rental income is based on contractual arrangements with its tenants. From the inception of a lease, if collection of substantially all of the lease payments is probable for a tenant, then rental income is recognized as earned over the life of the lease agreement on a straight-line basis. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue in amounts more or less than amounts currently due from tenants.

Interest Income
The Company's interest income is recognized based on contractual arrangements with its borrowers. The Company recognizes interest income on an accrual basis unless the Company determines that collectability of contractual amounts is not reasonably assured, at which point the interest on a given note is placed on non-accrual status and interest income is recognized on a cash basis.

Credit Losses
Losses from Operating Lease Receivables
We assess the probability of collecting substantially all rents under our leases, on a tenant-by-tenant basis, based on several factors, including, payment and default history, financial strength of the tenant and/or guarantors, historical and operating trends of the property, and the value of the underlying collateral, if any. If management determines that collection of substantially all of a tenant's lease payments is not probable, we will revert to recognizing such lease payments at the lesser of cash collected, lease income reflected on a straight-line basis, or another systematic basis plus variable rent when it becomes accruable and will reverse any recorded receivables related to that lease. In the event that management subsequently determines collection of substantially all of that tenant's lease payments is probable, management will reinstate and record all such receivables for the lease in accordance with the lease terms. The Company also maintains a general allowance for its lease receivables that management has determined are probable of collection. Accounts receivable, straight-line rent and related allowances are included in Other assets on the Company's Condensed Consolidated Balance Sheets and any offsetting reduction in income is included in rental income on the Company's Condensed Statements of Operations.

Credit Losses on Loans and Interest Receivables
Historically, the Company has at times entered into loans with certain of its tenants for working capital or other needs. We consider our loans to be incidental to our main business of acquiring and leasing healthcare real estate. Credit losses on financial instruments are measured using an expected credit loss ("CECL") model in evaluating the collectability of notes receivable and other financial instruments. The CECL impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, that considers forecasts of future economic conditions in addition to information about past events and current conditions. Under the CECL model, the Company estimates credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument and is required to record a credit loss expense (or reversal) in each reporting period. The Company evaluates factors such as its historical credit loss experience with the borrower or similar financial assets, current economic conditions, current and expected future financial condition of the borrower, as well as payment history of the borrower, along with other relevant factors for each borrower or similar instruments. If a sale of the borrower's collateral, such as the underlying business or real estate, is expected to repay amounts due to the Company, the Company will also evaluate the underlying collateral in measuring any expected credit loss. The Company's financial instruments included in the scope of the CECL guidance are the principal balances of its tenant
10
Notes to Condensed Consolidated Financial Statements - Continued
notes receivable and its net investment in a sales-type lease which are included in Other assets on the Company's Condensed Consolidated Balance Sheets.

We made an accounting policy election to exclude interest receivables from the credit loss reserve model. The Company recognizes interest income on an accrual basis unless the Company has determined that collectability of contractual amounts is not reasonably assured, at which point the note is placed on non-accrual status and interest income is recognized on a cash basis. Subsequently, when collectability of contractual amounts is reasonably assured, management will resume the accrual basis.

Income Taxes
The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes. No provision has been made for federal income taxes for the REIT; however, the Company has recorded income tax expense or benefit for the TRSs to the extent applicable. The Company intends at all times to qualify as a REIT under the Code. The Company must distribute at least 90% per annum of its REIT taxable income to its stockholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP) and meet other requirements to continue to qualify as a REIT.

Recent Accounting Pronouncements
The Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280) on November 27, 2023. The provisions of this update generally include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit and loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that entity's with a single reportable segment provide all of the disclosures required by the amendments in this update. This update is effective for annual reporting periods beginning after December 31, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements other than the new disclosure requirements, as we operate under a single reportable segment. Compliance with these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

NOTE 2. REAL ESTATE INVESTMENTS

As of September 30, 2024, we had gross investments of approximately $1.1 billion in 198 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as held for sale with a gross amount totaling approximately $6.4 million). The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables:
Property Type# of PropertiesGross Investment
(in thousands)
Medical Office Building96 $478,005 
Inpatient Rehabilitation Hospitals9 198,319 
Acute Inpatient Behavioral 5 130,535 
Specialty Centers37 117,989 
Physician Clinics31 94,965 
Surgical Centers and Hospitals9 58,474 
Behavioral Specialty Facilities9 45,067 
Long-term Acute Care Hospitals2 21,484 
Total198 $1,144,838 
11
Notes to Condensed Consolidated Financial Statements - Continued

State# of PropertiesGross Investment
(in thousands)
Texas17 $185,738 
Illinois18 132,814 
Ohio26 115,313 
Florida25 110,114 
Pennsylvania16 67,483 
All Others96 533,376 
Total198 $1,144,838 

Primary Tenant# of PropertiesGross Investment
(in thousands)
Lifepoint Health
5 $86,682 
US HealthVest3 77,964 
All Others (less than 4%)190 980,192 
Total198 $1,144,838 

NOTE 3. REAL ESTATE LEASES

Lessor Accounting
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2044. The Company’s leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property.

Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease.

Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of September 30, 2024, are as follows (in thousands):
2024 (three months ended December 31)$25,911 
202599,363 
202690,380 
202782,587 
202875,773 
2029 and thereafter411,035 
$785,049 

Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent increased rental income by approximately $0.7 million and $0.4 million, respectively, for the three months ended September 30, 2024 and 2023, and increased rental income by approximately $1.2 million and $2.2 million, respectively, for the nine months ended September 30, 2024 and 2023.

Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair
12
Notes to Condensed Consolidated Financial Statements - Continued
value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. At September 30, 2024, the Company had an aggregate gross investment of approximately $32.9 million in 10 real estate properties with purchase options exercisable at September 30, 2024 that had not been exercised.

Sales-type Lease
The Company has a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under this lease for the years ending December 31, as of September 30, 2024, are as follows (in thousands):

2024 (three months ended December 31)$88 
2025356 
2026367 
2027378 
2028389 
2029 and thereafter4,821 
Total undiscounted lease receivable6,399 
Discount(3,382)
Lease receivable$3,017 

The Company recognized interest income of approximately $0.1 million during each of the three months ended September 30, 2024 and 2023 and approximately $0.2 million during each of the nine months ended September 30, 2024 and 2023 related to this lease, which is included in other operating interest on the Company's Condensed Consolidated Statements of Operations.

Lessee Accounting
At September 30, 2024, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):

OperatingFinancing
2024 (three months ended December 31)$11 $37 
202544 154 
202644 154 
202745 154 
202846 154 
2029 and thereafter1,102 6,802 
Total undiscounted lease payments1,292 7,455 
Discount(526)(4,190)
Lease liabilities$766 $3,265 


13
Notes to Condensed Consolidated Financial Statements - Continued
The following table discloses other information regarding the ground leases.
Three Months Ended
September 30,
20242023
Operating leases:
Weighted-average remaining lease term in years (including renewal options)34.235.4
Weighted-average discount rate4.0 %4.0 %
Financing leases:
Weighted-average remaining lease term in years (including renewal options)39.140.1
Weighted-average discount rate4.3 %4.3 %

NOTE 4. REAL ESTATE ACQUISITIONS, DISPOSITION, AND ASSETS HELD FOR SALE

Acquisitions
During the third quarter of 2024, the Company acquired one physician clinic. Upon acquisition, the property was 100.0% leased to a tenant with a lease expiration in 2027. Amounts reflected in revenues and net income for the property for the three months ended September 30, 2024 were approximately $116,000 and $26,000, respectively, and transaction costs totaling approximately $123,000 were capitalized relating to this property acquisition.

During the second quarter of 2024, the Company acquired one inpatient rehabilitation facility. The property was 100.0% leased to a tenant with a lease expiration in 2039. Amounts reflected in revenues and net income for this property for the nine months ended September 30, 2024 was approximately $1.1 million and $0.8 million, respectively, and transaction costs totaling approximately $47,000 were capitalized relating to this property acquisition.

During the first quarter of 2024, the Company acquired four real estate properties in three transactions. Upon acquisition, the properties were 98.6% leased in the aggregate with lease expirations through 2039. Amounts reflected in revenues and net income for these properties for the nine months ended September 30, 2024 were approximately $2.1 million and $1.0 million, respectively, and transaction costs totaling approximately $0.3 million were capitalized relating to these property acquisitions.

The following table summarizes our property acquisitions for the nine months ended September 30, 2024:
Location
Property
Type (1)
Number of PropertiesDate
Acquired		Purchase
Price		Cash
Consideration		Real Estate
Other (2)
Square Footage
(000's)(000's)(000's)(000's)
New Bedford, MALTACH11/31/24$6,500 $6,540 $6,547 $(7)70,657 
Elkton, MDMOB13/25/244,500 4,578 4,757 (179)19,656 
Bemidji, MNMOB23/29/2423,200 23,179 23,375 (196)74,700 
San Antonio, TXIRF14/16/2423,500 23,547 23,547 — 38,009 
Camp Hill, PAPC17/22/246,200 6,308 6,323 (15)20,400 
$63,900 $64,152 $64,549 $(397)223,422 
(1) LTACH - Long-term Acute Care Hospital; MOB - Medical Office Building; IRF - Inpatient Rehabilitation Facility; PC - Physician Clinic
(2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition


14
Notes to Condensed Consolidated Financial Statements - Continued
The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the nine months ended September 30, 2024:
Relative
Fair Value		Estimated
Useful Life
(in thousands)(in years)
Land and land improvements$7,659 9.2
Building and building improvements53,116 35.0
Intangibles:
In-place lease intangibles3,774 3.7
Above-market lease intangibles121 5.0
Below-market lease intangibles(275)2.0
Total intangibles3,620 
Accounts payable, accrued liabilities and other liabilities assumed(194)
Accounts receivable and other assets acquired48 
Prorated rent, interest and operating expense reimbursement amounts collected(97)
Total cash consideration$64,152 

Disposition
During the third quarter of 2024, the Company disposed of an 11,200 square foot surgical center in Texas, and received net proceeds of approximately $1.0 million. The vacant property was previously classified as real estate property held for sale on the Company's Condensed Consolidated Balance Sheet. The Company recorded impairments on the property in previous quarters to adjust the carrying value of the property to its fair value less costs to sell, recorded a casualty loss due to vandalism at the property, and sold the property during the three months ended September 30, 2024, recording an immaterial gain on sale.

Real Estate Properties Held for Sale
The Company had one property classified as held for sale as of September 30, 2024 and two properties classified as held for sale as of December 31, 2023. The table below reflects the real estate assets classified as held for sale as of September 30, 2024 and December 31, 2023.

(Dollars in thousands)September 30, 2024December 31, 2023
Balance Sheet data:
Land$1,048 $1,576 
Building, improvements, and lease intangibles7,689 10,056 
8,737 11,632 
Accumulated depreciation(2,386)(4,166)
Real estate properties held for sale, net$6,351 $7,466 


15
Notes to Condensed Consolidated Financial Statements - Continued
NOTE 5. DEBT, NET

The table below details the Company's debt as of September 30, 2024 and December 31, 2023.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023Maturity Dates
Credit Facility:
Revolving Credit Facility$125,000 $50,000 3/26
A-3 Term Loan, net74,822 74,730 3/26
A-4 Term Loan, net124,607 124,522 3/28
A-5 Term Loan, net149,287 149,189 3/30
Mortgage Note Payable, net— 4,815 5/24
$473,716 $403,256 

Credit Facility
The Company's third amended and restated credit agreement, as amended (the "Credit Facility") is by and among
Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent. The Company amended the Credit Facility on October 16, 2024. See Note 14 – Subsequent Events on the Credit Facility refinancing.

As of September 30, 2024, the Credit Facility provided for a $150.0 million revolving credit facility (the "Revolving Credit Facility") and $350.0 million in term loans (the "Term Loans"). The Revolving Credit Facility was scheduled to mature on March 19, 2026 and included one 12-month option to extend the maturity date, subject to the satisfaction of certain conditions. The Term Loans include a seven-year term loan facility in the aggregate principal amount of $75.0 million (the "A-3 Term Loan"), which was scheduled to mature on March 29, 2026, a seven-year term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan"), which matures on March 19, 2028, and a seven-year and three-month term loan facility in the aggregate principal amount of $150.0 million (the "A-5 Term Loan") which matures on March 14, 2030. Loans under the Credit Facility are interest only with principal amounts due as of each facility's applicable maturity date. The Credit Facility allowed the Company to borrow, through the accordion feature, up to $700.0 million, including the ability to add and fund incremental term loans. The Company's material subsidiaries are guarantors of the obligations under the Credit Facility.

Amounts outstanding under the Revolving Credit Facility bore interest at a floating rate based on the Company's option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR plus 1.25% to 1.90% or (ii) a base rate plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. At September 30, 2024, the Company had $125.0 million outstanding under the Revolving Credit Facility with a weighted average interest rate of 6.58% and a borrowing capacity remaining of $25.0 million.

Amounts outstanding under the Term Loans will bear interest at a floating rate that is based, at the Company's option, on either (i) adjusted term SOFR or adjusted daily SOFR plus 1.65% to 2.30%, plus a simple SOFR adjustment equal to 0.10% per annum, or (ii) a base rate plus 0.65% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company has entered into interest rate swaps to fix the interest rates on the Term Loans. See Note 6 – Derivative Financial Instruments for more details on the interest rate swaps. At September 30, 2024, the Company had $350.0 million outstanding under the Term Loans with a fixed weighted average interest rate under the swaps of approximately 4.4%.

16
Notes to Condensed Consolidated Financial Statements - Continued
The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2024.

Mortgage Note Payable
During the three months ended June 30, 2024, the Company repaid its mortgage note payable totaling approximately $4.8 million.

NOTE 6. DERIVATIVE FINANCIAL INSTRUMENTS

Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.

As of September 30, 2024, the Company had fifteen outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $350.0 million, which mature between 2026 and 2030, at the maturity dates of the associated term loans (see Note 5 – Debt, net).

Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023.
Asset Derivatives Fair Value atLiability Derivatives Fair Value at
(Dollars in thousands)September 30, 2024December 31, 2023Balance Sheet ClassificationSeptember 30, 2024December 31, 2023Balance Sheet Classification
Interest rate swaps$10,492 $16,417 Other assets, net$476 $— Other liabilities, net

The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive income ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings.

Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s Term Loans. During the next twelve months, the Company estimates that an additional $5.4 million will be reclassified from AOCI as a decrease to interest expense.

17
Notes to Condensed Consolidated Financial Statements - Continued
Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income
The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and nine months ended September 30, 2024 and 2023.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(Dollars in thousands)2024202320242023
Amount of unrealized (loss) gain recognized in OCI on derivative$(8,749)$8,691 $1,824 $13,593 
Amount of gain reclassified from AOCI into interest expense$(2,725)$(2,738)$(8,225)$(7,222)
Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded
$6,253 $4,641 $17,301 $12,773 

Tabular Disclosures of Offsetting Derivatives
The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of September 30, 2024 and December 31, 2023. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets.
Offsetting of Derivative Assets (as of September 30, 2024)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized AssetsGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$10,492 $— $10,492 $(476)$— $10,016 

Offsetting of Derivative Liabilities (as of September 30, 2024)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Liabilities in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$(476)$— $(476)$476 $— $— 

Offsetting of Derivative Assets (as of December 31, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized AssetsGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$16,417 $— $16,417 $— $— $16,417 

18
Notes to Condensed Consolidated Financial Statements - Continued
Offsetting of Derivative Liabilities (as of December 31, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Liabilities in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$— $— $— $— $— $— 

Credit-risk-related Contingent Features
As of September 30, 2024, the Company did not have any derivatives in a net liability position. As of September 30, 2024, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.


NOTE 7. STOCKHOLDERS' EQUITY

Common Stock
The following table provides a reconciliation of the beginning and ending common stock balances for the nine months ended September 30, 2024 and for the year ended December 31, 2023:
(In thousands)Nine Months Ended
September 30, 2024		Year Ended
December 31, 2023
Balance, beginning of period27,61325,897
Issuance of common stock3131,385
Vested RSUs11— 
Restricted stock issued, net of withheld shares and forfeitures305331
Balance, end of period28,24227,613
_____________

ATM Program
The Company has an at-the-market offering program ("ATM Program"), with Piper Sandler & Co., Evercore Group L.L.C., Truist Securities, Inc., Regions Securities LLC, Robert W. Baird & Co. Incorporated, Fifth Third Securities, Inc. and Janney Montgomery Scott LLC, as sales agents (collectively, the “Agents”). Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $500.0 million. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the agreement and applicable law.

The Company's activity under the ATM Program during the nine months ended September 30, 2024 is detailed in the table below. As of September 30, 2024, the Company had approximately $426.3 million remaining that may be issued under the ATM Program.
Three Months Ended
September 30, 2024		Nine Months Ended
September 30, 2024
Shares issued (in thousands)
— 313
Net proceeds received (in millions)
— $7.5
Average gross sales price per share— $24.38


19
Notes to Condensed Consolidated Financial Statements - Continued
NOTE 8. NET INCOME (LOSS) PER COMMON SHARE

The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and nine months ended September 30, 2024 and 2023, respectively.

Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands, except per share data)2024202320242023
Net income (loss)$1,749 $3,492 $(5,013)$3,147 
          Participating securities' share in earnings(756)(622)(2,075)(1,995)
Net income (loss), less participating securities' share in earnings$993 $2,870 $(7,088)$1,152 
Weighted average Common Shares outstanding
Weighted average Common Shares outstanding
28,168 26,823 27,910 26,411 
Unvested restricted shares
(1,508)(1,309)(1,431)(1,471)
Weighted average Common Shares outstanding–Basic26,660 25,514 26,479 24,940 
Weighted average Common Shares outstanding –Diluted
26,660 25,514 26,479 24,940 
Basic Net Income (Loss) Per Common Share$0.04 $0.11 $(0.27)$0.05 
Diluted Net Income (Loss) Per Common Share$0.04 $0.11 $(0.27)$0.05 

NOTE 9. STOCK INCENTIVE PLAN

Adoption of the 2024 Incentive Plan
The 2024 Incentive Plan, as amended, (the "Plan") was approved by our stockholders at our annual meeting on May 2, 2024. The Plan replaced our 2014 Incentive Plan, as amended, (the "2014 Plan") which had expired on March 31, 2024. The Plan, which will expire on March 4, 2034, implements several changes from the previous 2014 Plan:
•Freezes all awards under the 2014 Plan as of its expiration date;
•Removes the "evergreen provision" which allowed for the incremental automatic increase in the number of shares of common stock reserved for issuance under the Plan;
•Increases the number of shares of common stock authorized for issuance under the Plan to 1,150,000; and
•Expands the types of awards that may be awarded under the Plan.
A summary of restricted stock activity for the three and nine months ended September 30, 2024 and 2023 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(Dollars and shares in thousands)2024202320242023
Stock-based awards, beginning of period1,417 1,203 1,374 1,708 
Stock in lieu of compensation98 57 157 141 
Stock awards97 114 182 220 
   Total stock granted195 171 339 361 
Vested shares (1)
(51)— (152)(692)
Forfeited shares(1)— (1)(3)
Stock-based awards, end of period1,560 1,374 1,560 1,374 
Amortization expense (1)
$2,255 $1,898 $6,514 $17,936 
___________
(1) Amortization expense for the nine months ended September 30, 2023 included accelerated amortization totaling approximately $11.8 million recognized during the three months ended March 31, 2023, upon the passing of our former CEO and President. These shares vested during the three months ended June 30, 2023.

20
Notes to Condensed Consolidated Financial Statements - Continued
Restricted Stock Issuances
On January 12, 2024, pursuant to the 2014 Incentive Plan and the Third Amended and Restated Alignment of Interest Program, the Company granted 79,533 shares of restricted stock to its employees, in lieu of salary, that will cliff vest between three and eight years. Of the shares granted, 43,292 shares of restricted stock were granted in lieu of compensation from the program pool and 36,241 shares of restricted stock were awarded based on the restriction period elected from the plan pool. Also, on January 12, 2024, pursuant to the 2014 Incentive Plan and the Non-Executive Officer Incentive Program, the Company granted 10,159 shares of restricted stock to certain employees that will cliff vest in five years.

On May 2, 2024, pursuant to the 2024 Incentive Plan, the Company granted an aggregate of 22,070 shares of restricted stock to its Board of Directors, which will cliff vest in three years. On May 16, 2024, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted an aggregate of 24,887 shares of restricted stock to its Board of Directors, in lieu of fees, that will cliff vest in three years. Of the shares granted, 15,553 shares of restricted stock were granted in lieu of compensation from the program pool and 9,334 shares of restricted stock were awarded based on the restriction period elected from the plan pool. Also, on June 3, 2024, pursuant to the 2024 Incentive Plan, the Company granted 7,000 shares of restricted stock to an employee that will cliff vest in five years.

During the third quarter of 2024, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted an aggregate of 195,447 shares of restricted stock to its employees, in lieu of salary and bonus compensation, which will cliff vest between three and eight years. Of the shares granted, 98,111 shares of restricted stock were granted in lieu of compensation from the program pool and 97,336 shares of restricted stock were awarded based on the restriction period elected from the plan pool.

Compensation Programs under the 2024 Incentive Plan
The Company's various programs under the 2024 Incentive Plan have been amended during 2024 for various items, including: (i) allowing for the grant of RSUs and other types of awards other than restricted stock; (ii) limiting the maximum elective deferral percentage amount of salary and bonus to 50% to the acquisition of restricted stock for certain participants (previously 100%); and (iii) limiting the duration of the restriction period election depending on the retirement eligibility date per those participant's employment agreement. The deferral and restriction period limitations were effective beginning January 1, 2024 for salary and other compensation deferrals and are now effective for performance periods commencing on and after July 1, 2024 for cash bonus deferrals.

Restricted Stock Units
The Plan, and previous 2014 Plan, provide for the award of restricted stock units ("RSUs"). The Company historically granted long-term incentive awards to its executive officers which was comprised of restricted stock that vested in 8 years, based on backward-looking performance metrics. On January 2, 2024, the Board approved and adopted a new incentive compensation structure for its executive officers, including the issuance of time-based and performance-based RSUs with three-year forward-looking performance targets beginning with an initial performance period beginning July 1, 2023.

On January 2, 2024, the Company granted performance-based and time-based RSUs to its executive officers under the 2014 Incentive Plan and the Third Amended and Restated Executive Officer Incentive Program. These RSUs with a grant date value totaling $2.6 million are forward-looking with a three-year performance period beginning July 1, 2023. The performance-based RSUs were valued by independent specialists utilizing a Monte Carlo simulation to calculate the weighted average grant date fair values of $13.67 per share for the Absolute TSR units and $20.77 per share for the Relative TSR units. The grant date fair value of the Time-based TSR units was based on the Company's stock price on the grant date of $26.62. The combined weighted average grant date fair value of the RSUs granted was $19.24 per share. The following assumptions were used in valuing the performance-based RSUs:

21
Notes to Condensed Consolidated Financial Statements - Continued
Volatility25.0 %
Dividend assumption5.4 %
Expected term3 years
Risk-free rate4.3 %
Stock price (per share)$26.62 

A summary of the Company's RSU activity during the three and nine months ended September 30, 2024 and 2023, respectively, is included in the table below, as well as compensation expense recognized from the amortization of the value of RSUs over the applicable vesting periods.
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars and RSUs in thousands)2024202320242023
Restricted Stock Units, beginning of period134 — — — 
Absolute TSR Performance-based RSUs granted (1)
— — 57 — 
Relative TSR Performance-based RSUs granted (1)
— — 43 — 
Time-based RSUs granted (2)
— — 34 — 
Total RSUs granted— — 134 — 
Vested RSUs (2)
(11)— (11)— 
Restricted Stock Units, end of period123 — 123 — 
Amortization expense$242 $— $876 $— 
Grant Date Value Remaining at period end to be Amortized During the Performance Period$1,694 $— $1,694 $— 
______________
(1) The number of Performance-based RSUs granted were based on target levels. Actual number of shares granted will be based on performance at the end of the performance period which is June 30, 2026. The Performance-based RSUs, if earned, will vest at the end of the performance period.
(2) The number of Time-based RSUs granted were based on target levels. One-third of these RSUs will vest on each of June 30, 2025 and 2026. The first tranche of the 11,206 Time-Based RSUs was fully amortized as of June 30, 2024 and vested on July 1, 2024, the next business day after June 30, 2024.

NOTE 10. OTHER ASSETS, NET

Other assets, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are detailed in the table below.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023
Notes receivable, net of credit loss reserve$20,280 $30,775 
Straight-line rent receivables, net19,711 18,481 
Fair value of interest rate swaps10,492 16,417 
Leasing commissions, net3,920 2,312 
Sales-type lessor receivable3,017 3,028 
Financing lease right-of-use assets2,442 2,486 
Prepaid assets2,294 1,203 
Accounts receivable, net2,137 2,739 
Above-market intangible assets, net2,126 2,645 
Interest receivable, net1,798 1,906 
Operating lease right of use assets706 729 
Deferred financing costs, net312 471 
Other641 684 
$69,876 $83,876 


22
Notes to Condensed Consolidated Financial Statements - Continued
The Company's notes receivable mainly included:

•At September 30, 2024 and December 31, 2023, notes receivable included a term loan totaling $3.8 million and $6.0 million, respectively, secured by all assets and ownership interests in seven long-term acute care hospitals and one inpatient rehabilitation hospital owned by the borrower. The term loan will be repaid in equal monthly installments of $250,000 through the maturity date of December 31, 2025 and bears interest at 9% per annum.

•At September 30, 2024 and December 31, 2023, notes receivable included a term loan totaling $17.0 million, and a revolving credit facility with $6.3 million and $5.4 million drawn, respectively, secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. At September 30, 2024, the Company had an unfunded commitment of $2.2 million on the revolving credit facility and an unfunded commitment of up to $2.0 million on an advancing term loan facility. The term loan bears interest at 9% per annum, with interest only payments due initially and then equal monthly installments of principal payments due beginning March 31, 2025. The term loan facility matures on December 31, 2032. The revolving credit facility bears interest at 9% per annum and matures on December 31, 2025. The advancing term loan may be funded at the Company's discretion, and bears interest at 9% per annum on any amount funded, that may be used by the borrower to pay existing liabilities of co-borrowers. The term loan, the revolving credit facility and the additional commitment all include a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of each note.

In the second quarter of 2024, the Company determined that the collectability of the term loan and revolver loan was not reasonably assured. The tenant/borrower has experienced challenges with patient census and employee staffing, which has impacted cash flows from operations and the consistency of rent and interest payments to the Company. In the second quarter of 2024, the Company valued the notes based on its estimated value of the underlying collateral. As a result, in the second quarter of 2024, the Company recorded an $11.0 million credit loss reserve on its notes receivable with the tenant and reversed approximately $1.4 million of interest and placed the notes on non-accrual status. Changes in cash flows of the business, changes in market data, such as market multiples, and other relevant data may drive a change in the estimated value of the underlying collateral. At September 30, 2024, however, the Company did not believe that there were any material changes to warrant a change in the credit loss reserve recorded in the second quarter of 2024.

•At September 30, 2024 and December 31, 2023, notes receivable also included a $2.2 million and $2.3 million, respectively, revolving credit facility. This note will be repaid in equal monthly installments of $40,000 beginning on November 1, 2024, through the maturity date of April 1, 2027. The revolving credit facility bears interest at 9% per annum, as well as a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of the note.

•At September 30, 2024, notes receivable also included a $2.0 million construction mortgage loan with a developer which is secured by the land, improvements, and personal property. The mortgage loan, which bears interest at 10% per annum, will be interest only until the principal is due at the earlier of the completion and acquisition of the property, or August 15, 2027.

The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance. We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable. The VIEs that we have identified at September 30, 2024 are summarized in the table below.
23
Notes to Condensed Consolidated Financial Statements - Continued
Classification
Carrying Amount
(in thousands)
Maximum Exposure to Loss
(in thousands)
Note receivable (term loan)$3,750 $3,750 
Note receivable (revolving credit facility)$2,220 $2,220 
Note receivable (mortgage note)$2,000 $2,000 
Notes receivable (revolving credit facility and term loan), net of credit loss$12,310 $12,310 

NOTE 11. OTHER LIABILITIES, NET

Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are detailed in the table below.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023
Prepaid rent$5,880 $5,378 
Security deposits2,951 3,765 
Below-market lease intangibles, net2,593 3,188 
Fair value of interest rate swaps476 — 
Financing lease liability3,265 3,277 
Operating lease liability766 775 
Other558 485 
$16,489 $16,868 

NOTE 12. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value.

Cash and cash equivalents and restricted cash - The carrying amount approximated the fair value. The fair value estimates were determined using level 1 inputs.

Notes and mortgage note receivable - The fair value was estimated using cash flow analyses, based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and were classified as level 2 inputs in the hierarchy. The fair value of notes receivable with one tenant was determined utilizing the fair value of the receivables' collateral, as the receivables are collateral-dependent, and were classified as level 3 inputs in the hierarchy.

Borrowings under our Credit Facility - The carrying amount approximated the fair value because the borrowings were based on variable market interest rates. The fair value estimates were determined using level 2 inputs.

Derivative financial instruments (Interest rate swaps) - The fair value was estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs were utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps were observable in active markets and were classified as level 2 inputs in the hierarchy.

Mortgage note payable - The fair value was estimated using cash flow analyses which were based on an assumed market rate of interest or at a rate consistent with the rates on mortgage notes assumed by the Company and were classified as level 2 inputs in the hierarchy.

The table below details the fair values and carrying values for our notes and mortgage note receivable, interest rate swaps, and mortgage note payable at September 30, 2024 and December 31, 2023, using level 2 and level 3 inputs.
24
Notes to Condensed Consolidated Financial Statements - Continued
September 30, 2024December 31, 2023
(Dollars in thousands)Carrying ValueFair ValueCarrying ValueFair Value
Notes and mortgage note receivable (Level 2)$7,970 $7,835 $8,340 $8,159 
Notes receivable, net of credit loss (1)
$12,310 $12,310 $22,435 $23,040 
Interest rate swap asset$10,492 $10,492 $16,417 $16,417 
Interest rate swap liability$476 $476 $— $— 
Mortgage note payable (principal amount)$— $— $4,821 $4,791 
___________________
(1) Calculated utilizing Level 3 inputs at September 30, 2024 and Level 2 inputs at December 31, 2023.

NOTE 13. COMMITMENTS AND CONTINGENCIES

Tenant Improvements
The Company may provide tenant improvement allowances in new or renewal leases for the purpose of refurbishing or renovating tenant space. The Company may also assume tenant improvement obligations included in leases acquired in its real estate acquisitions. As of September 30, 2024, the Company had approximately $26.0 million in commitments for tenant improvements. Six of these projects totaling $13.1 million, represent redevelopment projects of the buildings into different healthcare uses backed by long-term leases.

Capital Improvements
The Company has entered into contracts with various vendors for various capital improvement projects related to its portfolio. As of September 30, 2024, the Company had approximately $3.1 million in commitments for capital improvement projects. Six of these projects totaling $0.8 million, represent redevelopment projects of the buildings into different healthcare uses backed by long-term leases.

Legal Proceedings
The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's Consolidated Financial Statements.

NOTE 14. SUBSEQUENT EVENTS

Dividend Declared
On October 24, 2024, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.465 per share. The dividend is payable on November 22, 2024 to stockholders of record on November 8, 2024.

Credit Facility Refinancing
On October 16, 2024, the Company entered into a second amendment to the third amended and restated credit agreement (the "Amended Credit Facility") with a syndicate of lenders, under which Truist Bank serves as administrative agent. The Amended Credit Facility, among other things, (i) increased the Company's Revolving Credit Facility from $150.0 million to $400.0 million, (ii) extended the maturity date of the Revolving Credit Facility from March 19, 2026 to October 16, 2029, and (iii) lowered pricing on the Revolving Credit Facility by 10 to 30 basis points, depending on the Company's leverage ratio. Proceeds from the increased Revolving Credit Facility were used to repay the existing $75.0 million A-3 Term Loan which was scheduled to mature on March 29, 2026. In addition, amounts outstanding under the Revolving Credit Facility prior to the second Amendment will remain outstanding. Interest rate swaps previously entered into to fix the interest rates on the A-3 Term Loan will remain in place on the Revolving Credit Facility through their maturity on March 29, 2026.
25

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Disclosure Regarding Forward-Looking Statements
This report and other materials that Community Healthcare Trust Incorporated (the "Company") has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “believes”, “expects”, “may”, "will', “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, “anticipates” or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Thus, the Company’s actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company’s common stock, changes in the Company’s business strategy, availability, terms and deployment of capital, the Company’s ability to refinance existing indebtedness at or prior to maturity on favorable terms, or at all, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company’s competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, changes in interest rates, supply chain disruptions, labor conditions, the conflicts in Ukraine and the Middle East, and/or uncertainties related to the 2024 U.S. presidential election, and the other factors described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this report and the Company undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.

The purpose of this Management's Discussion and Analysis ("MD&A") is to provide an understanding of the Company's consolidated financial condition, results of operations and cash. MD&A is provided as a supplement to, and should be read in conjunction with, the Company's Condensed Consolidated Financial Statements and accompanying notes.

Overview
References such as "we," "us," "our," and "the Company" mean Community Healthcare Trust Incorporated, a Maryland corporation, and its consolidated subsidiaries.

We were organized in the State of Maryland on March 28, 2014. We are a self-administered, self-managed healthcare real estate investment trust, or REIT, that acquires and owns properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers.

Trends and Matters Impacting Operating Results
Management monitors factors and trends that it believes are important to the Company and the REIT industry in order to gauge their potential impact on the operations of the Company. Certain of the factors and trends that management believes may impact the operations of the Company are discussed below.
26
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Real Estate Acquisitions
During the first nine months of 2024, the Company acquired six real estate properties totaling approximately 223,000 square feet for an aggregate purchase price of approximately $63.9 million and cash consideration of approximately $64.2 million. Upon acquisition, the properties were 99.3% leased in the aggregate with lease expirations through 2039. These acquisitions were funded with net proceeds from equity sales through the ATM program and the Company's Revolving Credit Facility. See Note 4 – Real Estate Acquisitions, Disposition, and Assets Held for Sale to the Condensed Consolidated Financial Statements for more details on these acquisitions.

Real Estate Dispositions
During the third quarter of 2024, the Company disposed of an 11,200 square foot surgical center in Texas, received net proceeds of approximately $1.0 million, and recognized an immaterial gain on sale.

Acquisition Pipeline
The Company has four properties under definitive purchase agreements for an aggregate expected purchase price of approximately $8.8 million. The Company's expected returns on these investments range from 9.29% to 9.50%. The Company expects to close on these properties in the fourth quarter of 2024; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions with proceeds from the Company's Revolving Credit Facility.

The Company has seven properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $169.5 million. The Company's expected return on these investments will approximate 9.1% to 9.75%. The Company anticipates closing on these properties throughout 2025, 2026 and 2027; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close.

Leased Square Footage
As of September 30, 2024, our real estate portfolio was approximately 91.3% leased, excluding real estate properties held for sale. During the first nine months of 2024, we had expiring or terminated leases related to approximately 431,000 square feet, and we leased or renewed leases relating to approximately 427,000 square feet.

Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase.

At September 30, 2024, the Company had an aggregate gross investment of approximately $32.9 million in 10 real estate properties with purchase options exercisable at September 30, 2024 that had not been exercised.

Inflation
Periods of high and persistent inflation could cause an increase in our expenses, capital expenditures, and cost of our variable-rate borrowings which could have a material impact on our financial position or results of operations. Many of our lease agreements contain provisions designed to mitigate the adverse impact of inflation, including annual rent increases based on stated increases or CPI increases. In response to inflationary pressures, the Federal Reserve began raising interest rates in 2022. Though these higher interest rates have just begun to decline, these higher rates may adversely impact real estate asset values and increase our interest expense on our variable-rate borrowings under our revolving credit facility.

Executive Compensation
During the first quarter of 2024, the Company's Board approved and adopted certain changes to executive compensation. Through the adoption of the Third Amended and Restated Alignment of Interest Program, the Board established a maximum elective deferral percentage amount of 50% (previously 100%) of compensation allowed to be deferred and applied to the acquisition of restricted stock for certain participants in the program, and limited the
27
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
duration of the restriction period election depending on each individual's retirement eligibility date. These changes were effective beginning January 1, 2024 for salary and other compensation deferrals and are now effective beginning July 1, 2024 for cash bonus deferrals.

Further, the Board approved and adopted a new long-term incentive compensation structure for its executive officers, which includes the issuance of time-based RSUs and performance-based RSUs with three-year forward-looking performance targets. Historically, the Company had granted long-term incentive awards to its executive officers comprised of restricted stock that vested in eight years, based on backward-looking performance metrics. See Note 9 – Stock Incentive Plan for more details.

Results of Operations
The Company's results of operations for the three and nine months ended September 30, 2024 compared to the same period in 2023 were impacted by real estate acquisitions, lease receivable, interest and loan loss reserves recognized in the second quarter of 2024 related to a tenant, the amortization of non-cash compensation, including the accelerated amortization of unvested restricted shares upon the passing of the Company's former CEO and President in the first quarter of 2023, the new executive compensation program implemented in the first quarter of 2024, as well as other items discussed in more detail below.

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023
The table below shows our results of operations for the three months ended September 30, 2024 compared to the same period in 2023 and the effect of changes in those results from period to period on our net income.
Three Months Ended September 30,Increase (Decrease)
(Dollars in thousands)
20242023$%
REVENUES
Rental income$29,335 $27,690 $1,645 5.9 %
Other operating interest, net304 1,045 (741)n/m
29,639 28,735 904 3.1 %
EXPENSES
Property operating5,986 5,456 (530)(9.7)%
General and administrative4,935 3,618 (1,317)(36.4)%
Depreciation and amortization10,927 11,208 281 2.5 %
21,848 20,282 (1,566)(7.7)%
OTHER (EXPENSE) INCOME
Gain on sale (impairment) of depreciable real estate asset5 (102)107 n/m
Interest expense(6,253)(4,641)(1,612)(34.7)%
Deferred income tax expense— (221)221 n/m
Interest and other income, net206 3 203 n/m
(6,042)(4,961)(1,081)21.8 %
NET INCOME$1,749 $3,492 $(1,743)(49.9)%
___________
n/m-not meaningful

Revenues
Rental income increased approximately $1.6 million, or 5.9%, for the three months ended September 30, 2024 compared to the same period in 2023. Rental income on properties acquired during 2023 and 2024 resulted in additional rental income of approximately $2.7 million in 2024 compared to 2023, offset partially by the impact of moving a tenant to cash basis in 2024 resulting in a reduction of approximately $0.8 million, with the remaining reduction due mainly to lease terminations, including two Genesis Care leases with the Company that they rejected in 2023 as part of their bankruptcy.
28
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued

Other operating interest decreased approximately $0.7 million for the three months ended September 30, 2024 compared to the same period in 2023 due mainly to placing a tenant note on non-accrual and reversing interest due from that tenant, as well as a reduction in interest on notes due to reduced principal balances from payments received.

Expenses
Property operating expenses increased approximately $0.5 million, or 9.7%, for the three months ended September 30, 2024 compared to the same period in 2023 due mainly to additional expenses on properties acquired during 2023 and 2024.

General and administrative expenses increased approximately $1.3 million, or 36.4%, for the three months ended September 30, 2024 compared to the same period in 2023 due mainly to compensation-related expenses. The non-cash amortization of deferred compensation increased approximately $0.6 million and cash compensation increased approximately $0.7 million for the three months ended September 30, 2024 compared to the same period in 2023 due to the issuance of additional restricted shares and from the impact of adopting the new executive compensation program in January 2024 which included the grant of 3-year forward-looking restricted stock units, as well as limiting the maximum elective deferral percentage amount of salary and bonus to 50% (previously 100%) as described in more detail in Note 9 – Stock Incentive Plan to the Condensed Consolidated Financial Statements.

Depreciation and amortization expense decreased approximately $0.3 million, or 2.5%, for the three months ended September 30, 2024 compared to the same period in 2023. This decrease was due mainly to the following:
•Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $1.9 million;
•Depreciation and amortization on the two properties classified as held for sale during the second and fourth quarters of 2023 resulted in a decrease of approximately $1.3 million;
•Accelerated amortization of lease intangibles on the two GenesisCare properties where the leases were rejected resulted in a decrease of approximately $1.5 million;
•Depreciation and amortization on real estate acquired during 2023 and 2024 resulted in an increase of approximately $1.3 million; and
•Depreciation on tenant and other capital improvements resulted in an increase of approximately $3.2 million.

Interest expense
Interest expense increased approximately $1.6 million, or 34.7%, for the three months ended September 30, 2024 compared to the same period in 2023 due mainly to increases in the weighted average balance and interest rates on the revolving credit facility.

Deferred income tax expense
Deferred income tax expense decreased approximately $0.2 million for the three months ended September 30, 2024 compared to the same period in 2023. During the three months ended September 30, 2023, the Company recorded an additional valuation allowance on its deferred tax asset.

Interest and other income, net
Interest and other income, net increased approximately $0.2 million for the three months ended September 30, 2024 compared to the same period in 2023. During the three months ended September 30, 2023, the Company received earnest money on a terminated contract on a property held for sale.

29
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023
The table below shows our results of operations for the nine months ended September 30, 2024 compared to the same period in 2023 and the effect of changes in those results from period to period on our net (loss) income.
Nine Months Ended
September 30,		Increase (Decrease)
(Dollars in thousands)
20242023$%
REVENUES
Rental income
$85,582 $80,582 $5,000 6.2 %
Other operating interest, net
906 3,139 (2,233)n/m
86,488 83,721 2,767 3.3 %
EXPENSES
Property operating
17,349 15,115 (2,234)(14.8)%
General and administrative
14,249 23,610 9,361 39.6 %
Depreciation and amortization
31,981 29,445 (2,536)(8.6)%
63,579 68,170 4,591 6.7 %
OTHER (EXPENSE) INCOME
Impairment of depreciable real estate asset(135)(102)(33)(32.4)%
Interest expense
(17,301)(12,773)(4,528)(35.4)%
Credit loss reserve(11,000)— (11,000)n/m
Deferred income tax expense
— (306)306 n/m
Interest and other income, net
514 777 (263)(33.8)%
(27,922)(12,404)(15,518)n/m
NET (LOSS) INCOME$(5,013)$3,147 $(8,160)n/m
n/m - not meaningful

Revenues
Rental income increased approximately $5.0 million, or 6.2%, for the nine months ended September 30, 2024 compared to the same period in 2023 due mainly to rental income on properties acquired during 2023 and 2024 resulting in additional rental income of approximately $9.2 million, offset partially by the impact of moving a tenant to cash basis in the second quarter of 2024 totaling approximately $1.9 million (including $0.9 million of straight-line rent) with the remaining reduction due mainly to lease terminations, including two Genesis Care leases with the Company that they rejected in 2023 as part of their bankruptcy.

Other operating interest decreased $2.2 million for the nine months ended September 30, 2024 compared to the same period in 2023 due mainly to placing a tenant note on non-accrual and reversing interest due from that tenant, as well as a reduction in interest on notes due to reduced principal balances from payments received.

Expenses
Property operating expenses increased approximately $2.2 million, or 14.8%, for the nine months ended September 30, 2024 compared to the same period in 2023 due mainly to the following:

•Expenses on properties acquired during 2023 and 2024 increased property operating expenses by approximately $1.5 million;
•Property insurance resulted in an increase of approximately $0.2 million;
•Snow plow and landscaping services resulted in an increase of approximately $0.2 million;
•Repairs and maintenance expenses resulted in an increase of approximately $0.2 million; and
•Amortization of leasing commissions resulted in an increase of approximately $0.1 million.

30
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
General and administrative expenses decreased approximately $9.4 million, or 39.6% for the nine months ended September 30, 2024 compared to the same period in 2023 due mainly to the following:

•Non-cash accelerated amortization of deferred compensation in the first quarter of 2023 for non-vested restricted common shares held by former CEO and President Timothy Wallace at the time of his passing in March 2023 accounted for a decrease of approximately $11.8 million; offset partially by
•An increase in the non-cash amortization of other deferred compensation of approximately $1.3 million and cash compensation of approximately $1.4 million for the nine months ended September 30, 2024 compared to the same period in 2023 due to the issuance of additional restricted shares and from the impact of adopting the new executive compensation program in January 2024 which included the grant of 3-year forward-looking restricted stock units, as well as limiting the maximum elective deferral percentage amount of salary and bonus to 50% (previously 100%) as described in more detail in Note 9 – Stock Incentive Plan to the Condensed Consolidated Financial Statements.

Depreciation and amortization expense increased approximately $2.5 million, or 8.6%, for the nine months ended September 30, 2024 compared to the same period in 2023. This increase was comprised mainly of the following:

•Acquisitions of real estate in 2023 and 2024 resulted in an increase of approximately $4.2 million;
•Tenant improvements and other capital expenditures resulted in an increase of approximately $4.2 million; offset against
•Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $2.8 million;
•Accelerated amortization of lease intangibles on the two GenesisCare properties in 2023 where the leases were rejected resulted in a decrease of approximately $1.5 million; and
•Depreciation and amortization on the two properties classified as held for sale during the second and fourth quarters of 2023 ceased at that time resulting in a decrease of approximately $1.5 million.

Interest expense
Interest expense increased approximately $4.5 million, or 35.4%, for the nine months ended September 30, 2024 compared to the same period in 2023. Interest due under the Credit Facility increased approximately $4.2 million due mainly to an increase in the revolving credit facility balance and a rise in interest rates (See Note 5 – Debt, net to the Condensed Consolidated Financial Statements), and the maturity of two interest rate swaps, which were replaced with two forward-starting interest swaps (See Note 6 – Derivative Financial Instruments to the Condensed Consolidated Financial Statements). Also, capitalized interest on redevelopment projects decreased approximately $0.4 million for the nine months ended September 30, 2024 compared to the same period in 2023. Mortgage interest decreased approximately $0.1 million for the nine months ended September 30, 2024 compared to the same period in 2023 due to the repayment of the mortgage note at maturity.

Credit loss reserve
Credit loss reserve totaling $11.0 million was recorded during the second quarter of 2024 related to notes receivable with a geriatric inpatient behavioral hospital tenant. See Note 10 – Other Assets, net for more details on the credit loss reserve.

Deferred income tax expense
Deferred income tax expense decreased approximately $0.3 million for the nine months ended September 30, 2024 compared to the same period in 2023. During the nine months ended September 30, 2023, the Company recorded an additional valuation allowance on its deferred tax asset.

Interest and other income, net
Interest and other income, net decreased approximately $0.3 million, or 33.8%, for the nine months ended September 30, 2024 compared to the same period in 2023. During the nine months ended September 30, 2023, the Company recognized a net casualty gain relating to a property totaling $0.7 million. During the second quarter of
31
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
2024, the Company recorded into income an undistributed allowance for tenant improvements totaling $0.3 million for a lease that expired on June 30, 2024. Also, during the nine months ended September 30, 2024, the Company recorded into income $0.2 million of earnest money on a terminated contract on a property held for sale.
Non-GAAP Financial Measures and Key Performance Indicators
Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds from Operations ("FFO") and Adjusted Funds from Operations ("AFFO")
FFO is an operating performance measure adopted by the National Association of Real Estate Investment Trusts, Inc. (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to net income (calculated in accordance with GAAP), excluding gains or losses from the sale of certain real estate assets, gains and losses from change in control, impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity, plus depreciation and amortization related to real estate properties, and after adjustments for unconsolidated partnerships and joint ventures. NAREIT also provides REITs with an option to exclude gains, losses and impairments of assets that are incidental to the main business of the REIT from the calculation of FFO.

In addition to FFO, the Company presents AFFO and AFFO per share. The Company defines AFFO as FFO, excluding certain expenses related to closing costs of properties acquired accounted for as business combinations and mortgages funded, excluding straight-line rent and the amortization of stock-based compensation, and including or excluding other non-cash items from time to time. AFFO presented herein may not be comparable to similar measures presented by other real estate companies due to the fact that not all real estate companies use the same definition.

Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management believes FFO, AFFO, FFO per share and AFFO per share provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, losses and impairment of incidental assets, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO, AFFO, FFO per share and AFFO per share can facilitate comparisons of operating
32
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
performance between periods. The table below reconciles net income (loss) to FFO and AFFO for the three and nine months ended September 30, 2024 compared to the same periods in 2023.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands, except per share amounts)2024202320242023
Net income (loss) (1) (2) (3)
$1,749 $3,492 $(5,013)$3,147 
Real estate depreciation and amortization
11,077 11,375 32,350 29,756 
(Gain on sale) impairment of depreciable real estate asset (2)
(5)102 135 102 
Credit loss reserve (4)
— — 11,000 — 
FFO12,821 14,969 38,472 33,005 
Straight-line rent (1)
(679)(444)(1,230)(2,180)
Stock-based compensation
2,497 1,898 7,390 6,137 
Accelerated amortization of stock-based compensation (3)
— — — 11,799 
Net gain from insurance recovery on casualty loss (2)
— — — (706)
AFFO$14,639 $16,423 $44,632 $48,055 
FFO per diluted common share$0.48 $0.58 $1.44 $1.29 
AFFO per diluted common share$0.55 $0.63 $1.67 $1.88 
Weighted average common shares outstanding - diluted (5)
26,853 26,025 26,781 25,538 
___________________
(1) During the three months ended June 30, 2024, the Company placed leases related to a tenant on cash basis and reversed rent and placed notes related to the tenant on non-accrual and reversed interest totaling approximately $3.2 million, including straight-line rent of approximately $0.9 million.
(2) During the three months ended June 30, 2023, the Company recognized a $0.7 million net casualty gain from insurance proceeds received related to one property. The Company recorded impairments on the property in previous quarters based on contracts to sell, and sold the property during the three months ended September 30, 2024, recording an immaterial gain on sale.
(3) During the three months ended March 31, 2023, the Company accelerated the amortization of stock-based compensation totaling $11.8 million upon the passing of our former CEO and President.
(4) During the three months ended June 30, 2024, the Company recorded an $11.0 million credit loss reserve related to notes receivable that are incidental to the Company's main business with a geriatric inpatient behavioral hospital tenant.
(5) Diluted weighted average common shares outstanding for FFO and AFFO are calculated based on the treasury method, rather than the 2-class method used to calculate earnings per share.

Net Operating Income ("NOI")
NOI is a key performance indicator. NOI is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties and other investments before general and administrative expenses, depreciation and amortization expense, gains or loss on the sale of real estate properties or other investments, interest expense, and income tax expense. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. The Company's use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing NOI.


33
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
The table below reconciles net income (loss) to NOI for the three and nine months ended September 30, 2024 compared to the same periods in 2023.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2024202320242023
Net income (loss) (1) (2)
$1,749 $3,492 $(5,013)$3,147 
General and administrative (3)
4,935 3,618 14,249 11,811 
Accelerated amortization of stock-based compensation— — — 11,799 
Depreciation and amortization10,927 11,208 31,981 29,445 
(Gain on sale) impairment of depreciable real estate asset (2)
(5)102 135 102 
Credit loss reserve (4)
— — 11,000 — 
Interest expense6,253 4,641 17,301 12,773 
Deferred income tax expense— 221 — 306 
Interest and other income, net(206)(3)(514)(777)
NOI$23,653 $23,279 $69,139 $68,606 
____________
(1) During the three months ended June 30, 2024, the Company placed leases related to a tenant on cash basis and reversed rent and placed notes related to the tenant on non-accrual and reversed interest totaling approximately $3.2 million, including straight-line rent of approximately $0.9 million.
(2) During the three months ended June 30, 2023, the Company recognized a $0.7 million net casualty gain from insurance proceeds received related to one property. The Company recorded impairments on the property in previous quarters based on contracts to sell, and sold the property during the three months ended September 30, 2024, recording an immaterial gain on sale.
(3) During the three months ended March 31, 2023, the Company accelerated the amortization of stock-based compensation totaling $11.8 million upon the passing of our former CEO and President.
(4) During the three months ended June 30, 2024, the Company recorded an $11.0 million credit loss reserve related to notes receivable that are incidental to the Company's main business with a geriatric inpatient behavioral hospital tenant.

EBITDAre and Adjusted EBITDAre
The Company uses the NAREIT definition of EBITDAre which is net income or loss plus interest expense, income tax expense, and depreciation and amortization, plus losses or minus gains on the disposition of depreciable property, including losses/gains on change of control, plus impairment write-downs of depreciable property and of investments in unconsolidated affiliates caused by a decrease in value of depreciable property in the affiliate, plus or minus adjustments to reflect the entity's share of EBITDAre of unconsolidated affiliates and consolidated affiliates with non-controlling interest. The Company also presents Adjusted EBITDAre which is EBITDAre before non-cash stock-based compensation expense.

We consider EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.


34
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
The table below reconciles net income (loss) to EBITDAre and Adjusted EBITDAre for the three and nine months ended September 30, 2024 compared to the same periods in 2023.

Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2024202320242023
Net (loss) income (1) (2)
$1,749 $3,492 $(5,013)$3,147 
Interest expense6,253 4,641 17,301 12,773 
Depreciation and amortization10,927 11,208 31,981 29,445 
Deferred income tax expense— 221 — 306 
(Gain on sale) impairment of depreciable real estate asset (2)
(5)102 135 102 
EBITDAre
$18,924 $19,664 $44,404 $45,773 
Non-cash stock-based compensation expense (3)
2,497 1,898 7,390 6,137 
Accelerated amortization of stock-based compensation— — — 11,799 
Net gain from insurance recovery on casualty loss— — — (706)
Credit loss reserve (4)
— — 11,000 — 
Adjusted EBITDAre
$21,421 $21,562 $62,794 $63,003 
_____________
(1) During the three months ended June 30, 2024, the Company placed leases related to a tenant on cash basis and reversed rent and placed notes related to the tenant on non-accrual and reversed interest totaling approximately $3.2 million, including straight-line rent of approximately $0.9 million.
(2) During the three months ended June 30, 2023, the Company recognized a $0.7 million net casualty gain from insurance proceeds received related to one property. The Company recorded impairments on the property in previous quarters based on contracts to sell, and sold the property during the three months ended September 30, 2024, recording an immaterial gain on sale.
(3) During the three months ended March 31, 2023, the Company accelerated the amortization of stock-based compensation totaling $11.8 million upon the passing of our former CEO and President.
(4) During the three months ended June 30, 2024, the Company recorded an $11.0 million credit loss reserve related to notes receivable that are incidental to the Company's main business with a geriatric inpatient behavioral hospital tenant.

Liquidity and Capital Resources
The Company monitors its liquidity and capital resources and relies on several key indicators in its assessment of capital markets for financing acquisitions and other operating activities as needed, including the following:

•Leverage ratios and financial covenants included in our Credit Facility;

•Dividend payout percentage; and

•Interest rates, underlying treasury rates, debt market spreads and equity markets.

The Company uses these indicators and others to compare its operations to its peers and to help identify areas in which the Company may need to focus its attention.

Financing Policy
The Company’s current financing policy limits aggregate debt (secured or unsecured) in excess of 40% of the Company's total capitalization, except for short-term, transitory periods. At September 30, 2024, our debt to total capitalization ratio (debt plus stockholders' equity plus accumulated depreciation) was approximately 40.0%.

Sources and Uses of Cash
The Company derives most of its revenues from its real estate properties. Our rental income represents our primary source of liquidity to fund our dividends, general and administrative expenses, property operating expenses, capital improvements on our properties, interest expense on our Credit Facility, and other expenses incurred related to managing our existing portfolio. To the extent additional resources are needed, the Company will fund its investment activity generally through equity or debt issuances either in the public or private markets or through proceeds from our Credit Facility, which was amended in October 2024 to provide additional financing for
35
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
acquisitions, capital improvements and other cash needs. See Note 14 – Subsequent Events to the Condensed Consolidated Financial Statements.

The Company expects to meet its liquidity needs through cash on hand, cash flows from operations and cash flows from sources discussed above. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Credit Facility
On October 16, 2024, the Company amended its Credit Facility to increase the Revolving Credit Facility capacity from $150.0 million to $400.0 million and extend the maturity through October 16, 2029. The amended Credit Facility also lowered pricing on the Revolving Credit Facility by 10 to 30 basis points, depending on the Company's leverage ratio. Proceeds from the increased Revolving Credit Facility were used to repay the existing $75.0 million A-3 Term Loan which was scheduled to mature on March 29, 2026. In addition, amounts outstanding under the Revolving Credit Facility prior to this amendment will remain outstanding. Interest rate swaps previously entered into to fix the interest rates on the A-3 Term Loan will remain in place on the Revolving Credit Facility through their maturity on March 29, 2026. See Note 5 – Debt, net and Note 14 – Subsequent Events to the Condensed Consolidated Financial Statements which provide more details on the Company's Credit Facility. At September 30, 2024, prior to the amendment, the Company had borrowing capacity remaining under the Revolving Credit Facility of approximately $25.0 million. At the time of closing on the amendment, on October 16, 2024, the Company had borrowing capacity remaining under the Revolving Credit Facility of approximately $198.0 million.

The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2024.

Ground Leases
At September 30, 2024, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. At September 30, 2024, the Company's aggregate obligation under these ground leases was approximately $8.7 million. See Note 3 – Real Estate Leases to the Condensed Consolidated Financial Statements.

Acquisition Pipeline
The Company has four properties under definitive purchase agreements for an aggregate expected purchase price of approximately $8.8 million. The Company's expected returns on these investments range from 9.29% to 9.50%. The Company expects to close on these properties in the fourth quarter of 2024; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions with proceeds from the Company's Revolving Credit Facility.

The Company has seven properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $169.5 million. The Company anticipates closing on these properties throughout 2025, 2026 and 2027; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions through net proceeds from equity sales through the ATM program and the Company's Revolving Credit Facility.

Tenant Improvements and Capital Improvements
Subject to Company approval, we may fund or reimburse tenants for tenant improvements, which are allowed for in certain leases, of up to approximately $26.0 million as of September 30, 2024. At September 30, 2024, six of these
36
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
projects, totaling $13.1 million, represented redevelopment projects on buildings with tenants backed by long-term leases.

The Company has also entered into contracts regarding certain capital expenditures with remaining commitments totaling approximately $3.1 million as of September 30, 2024. Six of these projects totaling $0.8 million, represent redevelopment projects of the buildings into different healthcare uses backed by long-term leases. Reimbursement of these expenditures by our tenants will be determined by each tenant's lease.

The Company expects to fund these expenditures through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility.

Notes Receivable
The Company has two notes with a tenant with unfunded commitments remaining totaling $4.2 million at September 30, 2024. See Note 10 – Other Assets, net to the Condensed Consolidated Financial Statements.

Automatic Shelf Registration Statement
On November 2, 2022, the Company filed an automatic shelf registration statement on Form S-3 with the Securities and Exchange Commission. The registration statement is for an indeterminate number of securities and is effective for three years. Under this registration statement, the Company has the capacity to offer and sell from time to time various types of securities, including common stock, preferred stock, depository shares, rights, debt securities, warrants and units.

Operating Activities
Cash flows provided by operating activities for the nine months ended September 30, 2024 and 2023 were approximately $43.2 million and $47.1 million, respectively. Cash flows provided by operating activities were generally provided by contractual rents and interest on our notes receivable, net of property operating expenses not reimbursed by the tenants and general and administrative expenses.

Investing Activities
Cash flows used in investing activities for the nine months ended September 30, 2024 and 2023 were approximately $83.2 million and $100.1 million, respectively. During the nine months ended September 30, 2024, the Company invested in six properties for an aggregate cash consideration of approximately $64.2 million and sold a property for cash consideration of approximately $1.0 million. Also, during the nine months ended September 30, 2024, the Company funded notes totaling $2.9 million, received payments on its notes totaling $2.4 million and funded capital expenditures on its existing portfolio totaling approximately $19.5 million.

During the nine months ended September 30, 2023, the Company invested in 17 properties and one land parcel for an aggregate cash consideration of approximately $92.0 million and funded notes receivable totaling approximately $2.0 million. Also, during the nine months ended September 30, 2023, the Company received payments on its notes receivable totaling $3.0 million, received insurance proceeds from a casualty loss totaling $2.3 million, and funded capital expenditures on its existing portfolio totaling approximately $11.5 million.

Financing Activities
Cash flows provided by financing activities for the nine months ended September 30, 2024 and 2023 were approximately $38.2 million and $45.9 million, respectively. During the nine months ended September 30, 2024, the Company (i) borrowed $75.0 million under its Revolving Credit Facility, (ii) repaid a mortgage note totaling approximately $4.8 million, (iii) paid dividends totaling approximately $38.6 million, (iv) completed equity offerings under its at-the-market program, resulting in net proceeds, net of underwriters' discount and offering costs, of approximately $7.3 million, and (v) upon the vesting of stock-based awards for certain employees, withheld shares and paid taxes totaling approximately $0.8 million on behalf of the employees.

During the nine months ended September 30, 2023, the Company (i) borrowed $48.0 million under its Revolving Credit Facility, (ii) completed equity offerings under its at-the-market program, resulting in net proceeds, net of
37
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
underwriters' discount and offering costs, of approximately $34.6 million, (iii) upon the vesting of stock-based awards for certain employees, withheld shares and paid taxes totaling approximately $1.0 million on behalf of employees, and (iv) paid dividends totaling approximately $35.6 million.

Security Deposits
As of September 30, 2024, the Company held approximately $2.9 million in security deposits for the benefit of the Company in the event the obligated tenant fails to perform under the terms of its respective lease. Generally, the Company may, at its discretion and upon notification to the tenant, draw upon the security deposits if there are any defaults under the leases.

Dividends
The Company is required to pay dividends to its stockholders at least equal to 90% of its taxable income in order to maintain its qualification as a REIT.

On October 24, 2024, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.465 per share. The dividend is payable on November 22, 2024 to stockholders of record on November 8, 2024. This rate equates to an annualized dividend of $1.86 per share.

The ability of the Company to pay dividends is dependent upon its ability to generate cash flows and to make accretive new investments.

Corporate Responsibility
The Company is committed to conducting its business according to the highest ethical standards and upholding its corporate responsibilities as a public company operating for the benefit of its stockholders. To that end, the Company modified its Governance Committee to be the Environmental, Social, and Governance (“ESG”) Committee with a revised charter included on the Company’s website at www.chct.reit. Among other duties, the ESG Committee meets at least annually to review and recommend to the Board the general strategy and initiatives regarding ESG matters, including the Company’s internal and external communications and disclosures.

The Company’s Board of Directors has adopted a revised Code of Ethics and Business Conduct that not only applies to its directors, officers, and other employees but also extends the Company's expectations that its vendors, service providers, contractors, and consultants will embrace the Company's commitment to integrity and personal responsibility by complying with this Code at all times. The Code of Ethics and Business Conduct includes the Company’s commitment to promote high standards of integrity by conducting its affairs honestly and ethically and to include in its periodic reports or other publicly available documents information and metrics related to internal monitoring, whistleblower, or reporting systems.

The Company’s whistleblower policy prohibits the Company and its affiliates and their officers, employees and agents from discharging, demoting, suspending, threatening, harassing or in any other manner discriminating against any employee for raising a concern. If an employee desires to raise a concern in a confidential or anonymous manner, the concern may be directed to the whistleblower officer at the Company’s whistleblower hotline. During the quarter ended September 30, 2024, the whistleblower officer received no whistleblower complaints.

The Company’s Information Technology infrastructure is cloud-based, utilizing Software as a Service (“SaaS”) applications for substantially all of its software requirements. Management has formed an IT Committee consisting of the Chief Executive Officer, Chief Financial Officer, and the Vice President of Information Technology to review and discuss information security matters and cyber security risks. The committee meets at least twice a year and reports to the Board of Directors as needed. The Company has adopted the Center of Internet Security (CIS) v8 IG1 cyber security controls including adopting an annual information security training program for its employees. The Company has partnered with a global cyber security leader to continuously and proactively manage and mitigate the ever growing list of cyber threats. As part of the managed monitoring and remediation platform, the Company benefits from a $100,000 breach prevention warranty. Since its inception, the Company has not had a security breach, and has not incurred any resulting expenses, penalties or settlements.
38


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We may use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We will not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. An interest rate swap is a contractual agreement entered into by two counterparties under which each agrees to make periodic payments to the other for an agreed period of time based on a notional amount of principal. Under the most common form of interest rate swap, known from our perspective as a floating-to-fixed interest rate swap, a series of floating, or variable, rate payments on a notional amount of principal is exchanged for a series of fixed interest rate payments on such notional amount. During the nine months ended September 30, 2024, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.

Changes In Internal Control Over Financial Reporting
There were no changes in our system of internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

39

PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

ITEM 1A.    RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, an investor should consider the risk factors included in its Annual Report on Form 10-K for the year ended December 31, 2023 and other reports that may be filed by the Company. There were no material changes in the risk factors presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

ITEM 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended September 30, 2024, the Company canceled shares of the Company's common stock to satisfy employee tax withholding obligation payable upon the vesting of stock-based awards, as follows:

PeriodTotal Number of
Shares Purchased		Average Price Paid
per share		Total Number of Shares purchased
as part of publicly announced plans
or programs		Maximum Number of Shares that may yet be purchased under the
plans or programs
July 1 - July 312,701 $23.22 — — 
August 1 - August 319,241 $18.56 — — 
September 1 - September 30— $— — — 
Total11,942 

ITEM 3.   DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.   MINE SAFETY DISCLOSURES

None.

ITEM 5.   OTHER INFORMATION

During the quarter ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

ITEM 6.    EXHIBITS
The exhibits required by Item 601 of Regulation S-K which are filed with this report are listed in the Exhibit Index and are hereby incorporated in by reference.
40


EXHIBIT INDEX
Exhibit No.
Description
3.1
3.2
10.1
31.1 *
31.2 *
32.1 **
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
___________________
(1)Filed as Exhibit 3.1 to Amendment No. 2 to the Registration Statement on Form S-11 of the Company filed with the Securities and Exchange Commission on May 6, 2015 (Registration No. 333-203210) and incorporated herein by reference.
(2)Filed as Exhibit 3.2 to the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 3, 2020 (File No. 001-37401) and incorporated herein by reference.
(3)Filed as Exhibit 10.1 to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on October 16, 2024 (File No. 001-37401) and incorporated herein by reference.

*    Filed herewith.
**    Furnished herewith.
†    Denotes executive compensation plan or arrangement.

41

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 29, 2024
COMMUNITY HEALTHCARE TRUST INCORPORATED
By:/s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President
By:/s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and Chief Financial Officer
42

Exhibit 31.1

Community Healthcare Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, David H. Dupuy, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Community Healthcare Trust Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 29, 2024
/s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President


Exhibit 31.2

Community Healthcare Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, William G. Monroe IV, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Community Healthcare Trust Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 29, 2024
/s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and Chief Financial Officer


Exhibit 32.1

Community Healthcare Trust Incorporated
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Community Healthcare Trust Incorporated (the "Company") for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David H. Dupuy, Chief Executive Officer and President of the Company, and I, William G. Monroe IV, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
i.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
ii.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: October 29, 2024
/s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President
/s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and
Chief Financial Officer


v3.24.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2024
Oct. 22, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-37401  
Entity Registrant Name Community Healthcare Trust Inc  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 46-5212033  
Entity Address, Address Line One 3326 Aspen Grove Drive  
Entity Address, Address Line Two Suite 150  
Entity Address, City or Town Franklin  
Entity Address, State or Province TN  
Entity Address, Postal Zip Code 37067  
City Area Code 615  
Local Phone Number 771-3052  
Title of 12(b) Security Common stock, $0.01 par value per share  
Trading Symbol CHCT  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   28,242,370
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001631569  
Current Fiscal Year End Date --12-31  
v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Real estate properties    
Land and land improvements $ 146,118 $ 136,532
Buildings, improvements, and lease intangibles 989,019 913,416
Personal property 326 299
Total real estate properties 1,135,463 1,050,247
Less accumulated depreciation (232,747) (200,810)
Total real estate properties, net 902,716 849,437
Cash and cash equivalents 2,836 3,491
Restricted cash 0 1,142
Real estate properties held for sale 6,351 7,466
Other assets, net 69,876 83,876
Total assets 981,779 945,412
Liabilities    
Debt, net 473,716 403,256
Accounts payable and accrued liabilities 14,422 12,032
Other liabilities, net 16,489 16,868
Total liabilities 504,627 432,156
Commitments and contingencies
Stockholders' Equity    
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.01 par value; 450,000 shares authorized; 28,242 and 27,613 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 282 276
Additional paid-in capital 702,014 688,156
Cumulative net income 83,843 88,856
Accumulated other comprehensive income 10,016 16,417
Cumulative dividends (319,003) (280,449)
Total stockholders’ equity 477,152 513,256
Total liabilities and stockholders' equity $ 981,779 $ 945,412
v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 50,000,000 50,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 450,000,000 450,000,000
Common stock, shares issued (in shares) 28,242,000 27,613,000
Common stock, shares outstanding (in shares) 28,242,000 27,613,000
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
REVENUES        
Rental income $ 29,335 $ 27,690 $ 85,582 $ 80,582
Other operating interest, net 304 1,045 906 3,139
Total revenue 29,639 28,735 86,488 83,721
EXPENSES        
Property operating 5,986 5,456 17,349 15,115
General and administrative [1] 4,935 3,618 14,249 23,610
Depreciation and amortization 10,927 11,208 31,981 29,445
Total expenses 21,848 20,282 63,579 68,170
OTHER (EXPENSE) INCOME        
Gain on sale (impairment) of depreciable real estate asset 5 (102) (135) (102)
Interest expense (6,253) (4,641) (17,301) (12,773)
Credit loss reserve 0 0 (11,000) 0
Deferred income tax expense 0 (221) 0 (306)
Interest and other income, net 206 3 514 777
Total other income (expense) (6,042) (4,961) (27,922) (12,404)
NET INCOME (LOSS) $ 1,749 $ 3,492 $ (5,013) $ 3,147
NET INCOME (LOSS) PER COMMON SHARE        
Net income (loss) per common share - Basic (in dollars per share) $ 0.04 $ 0.11 $ (0.27) $ 0.05
Net income (loss) per common share - Diluted (in dollars per share) $ 0.04 $ 0.11 $ (0.27) $ 0.05
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC (in shares) 26,660 25,514 26,479 24,940
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED (in shares) 26,660 25,514 26,479 24,940
[1]
(1) General and administrative expenses for the nine months ended September 30, 2024 included stock-based compensation expense totaling approximately $7.4 million. General and administrative expenses for the nine months ended September 30, 2023 included stock-based compensation expense totaling approximately $17.9 million, including the accelerated amortization of stock-based compensation totaling approximately $11.8 million recognized upon the passing of our former CEO and President in the first quarter of 2023. See Note 9 – Stock Incentive Plan.
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]      
Stock-based compensation expense   $ 7,400 $ 17,900
Accelerated amortization of stock-based compensation $ 11,800 $ 0 $ 11,799
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
NET INCOME (LOSS) $ 1,749 $ 3,492 $ (5,013) $ 3,147
Other comprehensive (loss) income:        
(Decrease) increase in fair value of cash flow hedges (8,749) 8,691 1,824 13,593
Reclassification for amounts recognized as interest expense (2,725) (2,738) (8,225) (7,222)
Total other comprehensive (loss) income (11,474) 5,953 (6,401) 6,371
COMPREHENSIVE (LOSS) INCOME $ (9,725) $ 9,445 $ (11,414) $ 9,518
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid in Capital
Cumulative Net Income
Accumulated Other Comprehensive Income
Cumulative Dividends
Beginning balance (in shares) at Dec. 31, 2022   0          
Beginning balance at Dec. 31, 2022 $ 496,814 $ 0 $ 259 $ 625,136 $ 81,142 $ 22,667 $ (232,390)
Balance, beginning of period (in shares) at Dec. 31, 2022 25,897,000   25,897,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock, net of issuance costs (in shares)     1,037,000        
Issuance of common stock, net of issuance costs $ 34,621   $ 11 34,610      
Stock-based compensation, net of forfeitures (in shares)     331,000        
Stock-based compensation, net of forfeitures 17,936   $ 3 17,933      
Shares withheld on vesting of stock-based compensation (963)     (963)      
(Decrease) Increase in fair value of cash flow hedges 13,593         13,593  
Reclassification for amounts recognized as interest expense (7,222)         (7,222)  
Net income (loss) 3,147       3,147    
Dividends to common stockholders (35,632)           (35,632)
Ending balance (in shares) at Sep. 30, 2023   0          
Ending balance at Sep. 30, 2023 522,294 $ 0 $ 273 676,716 84,289 29,038 (268,022)
Balance, end of period (in shares) at Sep. 30, 2023     27,265,000        
Beginning balance (in shares) at Dec. 31, 2022   0          
Beginning balance at Dec. 31, 2022 $ 496,814 $ 0 $ 259 625,136 81,142 22,667 (232,390)
Balance, beginning of period (in shares) at Dec. 31, 2022 25,897,000   25,897,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock, net of issuance costs (in shares) 1,385,000            
Ending balance (in shares) at Dec. 31, 2023 0 0          
Ending balance at Dec. 31, 2023 $ 513,256 $ 0 $ 276 688,156 88,856 16,417 (280,449)
Balance, end of period (in shares) at Dec. 31, 2023 27,613,000   27,613,000        
Beginning balance (in shares) at Jun. 30, 2023   0          
Beginning balance at Jun. 30, 2023 $ 505,325 $ 0 $ 265 657,057 80,797 23,085 (255,879)
Balance, beginning of period (in shares) at Jun. 30, 2023     26,541,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock, net of issuance costs (in shares)     552,000        
Issuance of common stock, net of issuance costs 17,769   $ 6 17,763      
Stock-based compensation, net of forfeitures (in shares)     172,000        
Stock-based compensation, net of forfeitures 1,898   $ 2 1,896      
(Decrease) Increase in fair value of cash flow hedges 8,691         8,691  
Reclassification for amounts recognized as interest expense (2,738)         (2,738)  
Net income (loss) 3,492       3,492    
Dividends to common stockholders (12,143)           (12,143)
Ending balance (in shares) at Sep. 30, 2023   0          
Ending balance at Sep. 30, 2023 $ 522,294 $ 0 $ 273 676,716 84,289 29,038 (268,022)
Balance, end of period (in shares) at Sep. 30, 2023     27,265,000        
Beginning balance (in shares) at Dec. 31, 2023 0 0          
Beginning balance at Dec. 31, 2023 $ 513,256 $ 0 $ 276 688,156 88,856 16,417 (280,449)
Balance, beginning of period (in shares) at Dec. 31, 2023 27,613,000   27,613,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock, net of issuance costs (in shares) 313,000   313,000        
Issuance of common stock, net of issuance costs $ 7,259   $ 3 7,256      
Stock-based compensation, net of forfeitures (in shares)     350,000        
Stock-based compensation, net of forfeitures 7,390   $ 3 7,387      
Shares withheld on vesting of stock-based compensation (in shares)     (34,000)        
Shares withheld on vesting of stock-based compensation (785)     (785)      
(Decrease) Increase in fair value of cash flow hedges 1,824         1,824  
Reclassification for amounts recognized as interest expense (8,225)         (8,225)  
Net income (loss) (5,013)       (5,013)    
Dividends to common stockholders $ (38,554)           (38,554)
Ending balance (in shares) at Sep. 30, 2024 0 0          
Ending balance at Sep. 30, 2024 $ 477,152 $ 0 $ 282 702,014 83,843 10,016 (319,003)
Balance, end of period (in shares) at Sep. 30, 2024 28,242,000   28,242,000        
Beginning balance (in shares) at Jun. 30, 2024   0          
Beginning balance at Jun. 30, 2024 $ 497,771 $ 0 $ 280 699,833 82,094 21,490 (305,926)
Balance, beginning of period (in shares) at Jun. 30, 2024     28,049,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock, net of issuance costs (in shares)     0        
Issuance of common stock, net of issuance costs (80)     (80)      
Stock-based compensation, net of forfeitures (in shares)     206,000        
Stock-based compensation, net of forfeitures 2,497   $ 2 2,495      
Shares withheld on vesting of stock-based compensation (in shares)     (13,000)        
Shares withheld on vesting of stock-based compensation (234)     (234)      
(Decrease) Increase in fair value of cash flow hedges (8,749)         (8,749)  
Reclassification for amounts recognized as interest expense (2,725)         (2,725)  
Net income (loss) 1,749       1,749    
Dividends to common stockholders $ (13,077)           (13,077)
Ending balance (in shares) at Sep. 30, 2024 0 0          
Ending balance at Sep. 30, 2024 $ 477,152 $ 0 $ 282 $ 702,014 $ 83,843 $ 10,016 $ (319,003)
Balance, end of period (in shares) at Sep. 30, 2024 28,242,000   28,242,000        
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]        
Dividend declared (in dollars per share) $ 0.4625 $ 0.4525 $ 1.3800 $ 1.3500
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
OPERATING ACTIVITIES    
Net (loss) income $ (5,013) $ 3,147
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 31,981 29,445
Other amortization 636 558
Stock-based compensation 7,390 6,137
Accelerated amortization of stock-based compensation 0 11,799
Straight-line rent receivable (1,230) (2,180)
Net gain from insurance recovery on casualty loss 0 (706)
Impairment of real estate asset, net of gain on sale 135 102
Credit loss reserve 11,000 0
Deferred income tax expense 0 306
Changes in operating assets and liabilities:    
Other assets (3,543) (3,082)
Accounts payable and accrued liabilities 2,263 3,337
Other liabilities (402) (1,772)
Net cash provided by operating activities 43,217 47,091
INVESTING ACTIVITIES    
Acquisitions of real estate (64,152) (91,993)
Proceeds from sale of real estate 965 0
Funding of notes receivable (2,875) (1,985)
Proceeds from the repayment of notes receivable 2,370 3,045
Insurance proceeds from casualty loss 0 2,273
Capital expenditures on existing real estate properties (19,483) (11,461)
Net cash used in investing activities (83,175) (100,121)
FINANCING ACTIVITIES    
Net borrowings on revolving credit facility 75,000 48,000
Mortgage note repayments (4,820) (94)
Dividends paid (38,554) (35,632)
Proceeds from issuance of common stock 7,492 34,766
Taxes paid on behalf of employees and shares withheld upon shares vesting (785) (963)
Equity issuance costs (172) (182)
Net cash provided by financing activities 38,161 45,895
Decrease in cash, cash equivalents and restricted cash (1,797) (7,135)
Cash, cash equivalents and restricted cash, beginning of period 4,633 12,068
Cash, cash equivalents and restricted cash, end of period 2,836 4,933
Supplemental Cash Flow Information:    
Interest paid (net of capitalized interest) 16,932 9,868
Invoices accrued for construction, tenant improvement, and other capitalized costs 5,124 4,922
Reclassification of registration statement costs incurred in prior years to equity issuance costs 269 145
(Decrease) increase in fair value of cash flow hedges 1,824 13,593
Income taxes paid 31 90
Capitalized interest $ 154 $ 514
v3.24.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Overview
Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of September 30, 2024, the Company had gross investments of approximately $1.1 billion in 198 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as an asset held for sale with a net investment totaling approximately $6.4 million. See Note 10 – Other Assets, net and Note 4 – Real Estate Acquisitions, Disposition, and Assets Held for Sale, respectively). The properties are located in 35 states, totaling approximately 4.4 million square feet in the aggregate and were approximately 91.3% leased, excluding the real estate asset held for sale, at September 30, 2024 with a weighted average remaining lease term of approximately 6.8 years. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm's review.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes, including among others, estimates related to impairment assessments, purchase price allocations, valuation of properties held for sale, allowances for accounts and interest receivables, and valuation of financial instruments. Actual results may materially differ from those estimates.

Cash and Cash Equivalents and Restricted Cash
Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash consisted of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Company's Condensed
Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows:
 Balance as of September 30,
(Dollars in thousands)20242023
Cash and cash equivalents$2,836 $3,885 
Restricted cash— 1,048 
Cash, cash equivalents and restricted cash$2,836 $4,933 

Rental Income
The primary source of revenue for the Company is generated through its leasing arrangements with its tenants which is accounted for under ASC Topic 842. The Company's rental income is based on contractual arrangements with its tenants. From the inception of a lease, if collection of substantially all of the lease payments is probable for a tenant, then rental income is recognized as earned over the life of the lease agreement on a straight-line basis. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue in amounts more or less than amounts currently due from tenants.

Interest Income
The Company's interest income is recognized based on contractual arrangements with its borrowers. The Company recognizes interest income on an accrual basis unless the Company determines that collectability of contractual amounts is not reasonably assured, at which point the interest on a given note is placed on non-accrual status and interest income is recognized on a cash basis.

Credit Losses
Losses from Operating Lease Receivables
We assess the probability of collecting substantially all rents under our leases, on a tenant-by-tenant basis, based on several factors, including, payment and default history, financial strength of the tenant and/or guarantors, historical and operating trends of the property, and the value of the underlying collateral, if any. If management determines that collection of substantially all of a tenant's lease payments is not probable, we will revert to recognizing such lease payments at the lesser of cash collected, lease income reflected on a straight-line basis, or another systematic basis plus variable rent when it becomes accruable and will reverse any recorded receivables related to that lease. In the event that management subsequently determines collection of substantially all of that tenant's lease payments is probable, management will reinstate and record all such receivables for the lease in accordance with the lease terms. The Company also maintains a general allowance for its lease receivables that management has determined are probable of collection. Accounts receivable, straight-line rent and related allowances are included in Other assets on the Company's Condensed Consolidated Balance Sheets and any offsetting reduction in income is included in rental income on the Company's Condensed Statements of Operations.

Credit Losses on Loans and Interest Receivables
Historically, the Company has at times entered into loans with certain of its tenants for working capital or other needs. We consider our loans to be incidental to our main business of acquiring and leasing healthcare real estate. Credit losses on financial instruments are measured using an expected credit loss ("CECL") model in evaluating the collectability of notes receivable and other financial instruments. The CECL impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, that considers forecasts of future economic conditions in addition to information about past events and current conditions. Under the CECL model, the Company estimates credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument and is required to record a credit loss expense (or reversal) in each reporting period. The Company evaluates factors such as its historical credit loss experience with the borrower or similar financial assets, current economic conditions, current and expected future financial condition of the borrower, as well as payment history of the borrower, along with other relevant factors for each borrower or similar instruments. If a sale of the borrower's collateral, such as the underlying business or real estate, is expected to repay amounts due to the Company, the Company will also evaluate the underlying collateral in measuring any expected credit loss. The Company's financial instruments included in the scope of the CECL guidance are the principal balances of its tenant
notes receivable and its net investment in a sales-type lease which are included in Other assets on the Company's Condensed Consolidated Balance Sheets.

We made an accounting policy election to exclude interest receivables from the credit loss reserve model. The Company recognizes interest income on an accrual basis unless the Company has determined that collectability of contractual amounts is not reasonably assured, at which point the note is placed on non-accrual status and interest income is recognized on a cash basis. Subsequently, when collectability of contractual amounts is reasonably assured, management will resume the accrual basis.

Income Taxes
The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes. No provision has been made for federal income taxes for the REIT; however, the Company has recorded income tax expense or benefit for the TRSs to the extent applicable. The Company intends at all times to qualify as a REIT under the Code. The Company must distribute at least 90% per annum of its REIT taxable income to its stockholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP) and meet other requirements to continue to qualify as a REIT.

Recent Accounting Pronouncements
The Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280) on November 27, 2023. The provisions of this update generally include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit and loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that entity's with a single reportable segment provide all of the disclosures required by the amendments in this update. This update is effective for annual reporting periods beginning after December 31, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements other than the new disclosure requirements, as we operate under a single reportable segment. Compliance with these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
v3.24.3
Real Estate Investments
 9 Months Ended
Sep. 30, 2024
Real Estate [Abstract]  
Real Estate Investments REAL ESTATE INVESTMENTS
As of September 30, 2024, we had gross investments of approximately $1.1 billion in 198 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as held for sale with a gross amount totaling approximately $6.4 million). The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables:
Property Type# of PropertiesGross Investment
(in thousands)
Medical Office Building96 $478,005 
Inpatient Rehabilitation Hospitals9 198,319 
Acute Inpatient Behavioral 5 130,535 
Specialty Centers37 117,989 
Physician Clinics31 94,965 
Surgical Centers and Hospitals9 58,474 
Behavioral Specialty Facilities9 45,067 
Long-term Acute Care Hospitals2 21,484 
Total198 $1,144,838 
State# of PropertiesGross Investment
(in thousands)
Texas17 $185,738 
Illinois18 132,814 
Ohio26 115,313 
Florida25 110,114 
Pennsylvania16 67,483 
All Others96 533,376 
Total198 $1,144,838 

Primary Tenant# of PropertiesGross Investment
(in thousands)
Lifepoint Health
5 $86,682 
US HealthVest3 77,964 
All Others (less than 4%)190 980,192 
Total198 $1,144,838 
v3.24.3
Real Estate Leases
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Real Estate Leases REAL ESTATE LEASES
Lessor Accounting
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2044. The Company’s leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property.

Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease.

Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of September 30, 2024, are as follows (in thousands):
2024 (three months ended December 31)$25,911 
202599,363 
202690,380 
202782,587 
202875,773 
2029 and thereafter411,035 
$785,049 

Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent increased rental income by approximately $0.7 million and $0.4 million, respectively, for the three months ended September 30, 2024 and 2023, and increased rental income by approximately $1.2 million and $2.2 million, respectively, for the nine months ended September 30, 2024 and 2023.

Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair
value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. At September 30, 2024, the Company had an aggregate gross investment of approximately $32.9 million in 10 real estate properties with purchase options exercisable at September 30, 2024 that had not been exercised.

Sales-type Lease
The Company has a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under this lease for the years ending December 31, as of September 30, 2024, are as follows (in thousands):

2024 (three months ended December 31)$88 
2025356 
2026367 
2027378 
2028389 
2029 and thereafter4,821 
Total undiscounted lease receivable6,399 
Discount(3,382)
Lease receivable$3,017 

The Company recognized interest income of approximately $0.1 million during each of the three months ended September 30, 2024 and 2023 and approximately $0.2 million during each of the nine months ended September 30, 2024 and 2023 related to this lease, which is included in other operating interest on the Company's Condensed Consolidated Statements of Operations.

Lessee Accounting
At September 30, 2024, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):

OperatingFinancing
2024 (three months ended December 31)$11 $37 
202544 154 
202644 154 
202745 154 
202846 154 
2029 and thereafter1,102 6,802 
Total undiscounted lease payments1,292 7,455 
Discount(526)(4,190)
Lease liabilities$766 $3,265 
The following table discloses other information regarding the ground leases.
Three Months Ended
September 30,
20242023
Operating leases:
Weighted-average remaining lease term in years (including renewal options)34.235.4
Weighted-average discount rate4.0 %4.0 %
Financing leases:
Weighted-average remaining lease term in years (including renewal options)39.140.1
Weighted-average discount rate4.3 %4.3 %
v3.24.3
Real Estate Acquisitions, Disposition, And Assets Held For Sale
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Real Estate Acquisitions, Disposition And Assets Held For Sale REAL ESTATE ACQUISITIONS, DISPOSITION, AND ASSETS HELD FOR SALE
Acquisitions
During the third quarter of 2024, the Company acquired one physician clinic. Upon acquisition, the property was 100.0% leased to a tenant with a lease expiration in 2027. Amounts reflected in revenues and net income for the property for the three months ended September 30, 2024 were approximately $116,000 and $26,000, respectively, and transaction costs totaling approximately $123,000 were capitalized relating to this property acquisition.

During the second quarter of 2024, the Company acquired one inpatient rehabilitation facility. The property was 100.0% leased to a tenant with a lease expiration in 2039. Amounts reflected in revenues and net income for this property for the nine months ended September 30, 2024 was approximately $1.1 million and $0.8 million, respectively, and transaction costs totaling approximately $47,000 were capitalized relating to this property acquisition.

During the first quarter of 2024, the Company acquired four real estate properties in three transactions. Upon acquisition, the properties were 98.6% leased in the aggregate with lease expirations through 2039. Amounts reflected in revenues and net income for these properties for the nine months ended September 30, 2024 were approximately $2.1 million and $1.0 million, respectively, and transaction costs totaling approximately $0.3 million were capitalized relating to these property acquisitions.

The following table summarizes our property acquisitions for the nine months ended September 30, 2024:
Location
Property
Type (1)
Number of PropertiesDate
Acquired		Purchase
Price		Cash
Consideration		Real Estate
Other (2)
Square Footage
(000's)(000's)(000's)(000's)
New Bedford, MALTACH11/31/24$6,500 $6,540 $6,547 $(7)70,657 
Elkton, MDMOB13/25/244,500 4,578 4,757 (179)19,656 
Bemidji, MNMOB23/29/2423,200 23,179 23,375 (196)74,700 
San Antonio, TXIRF14/16/2423,500 23,547 23,547 — 38,009 
Camp Hill, PAPC17/22/246,200 6,308 6,323 (15)20,400 
$63,900 $64,152 $64,549 $(397)223,422 
(1) LTACH - Long-term Acute Care Hospital; MOB - Medical Office Building; IRF - Inpatient Rehabilitation Facility; PC - Physician Clinic
(2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition
The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the nine months ended September 30, 2024:
Relative
Fair Value		Estimated
Useful Life
(in thousands)(in years)
Land and land improvements$7,659 9.2
Building and building improvements53,116 35.0
Intangibles:
In-place lease intangibles3,774 3.7
Above-market lease intangibles121 5.0
Below-market lease intangibles(275)2.0
Total intangibles3,620 
Accounts payable, accrued liabilities and other liabilities assumed(194)
Accounts receivable and other assets acquired48 
Prorated rent, interest and operating expense reimbursement amounts collected(97)
Total cash consideration$64,152 

Disposition
During the third quarter of 2024, the Company disposed of an 11,200 square foot surgical center in Texas, and received net proceeds of approximately $1.0 million. The vacant property was previously classified as real estate property held for sale on the Company's Condensed Consolidated Balance Sheet. The Company recorded impairments on the property in previous quarters to adjust the carrying value of the property to its fair value less costs to sell, recorded a casualty loss due to vandalism at the property, and sold the property during the three months ended September 30, 2024, recording an immaterial gain on sale.

Real Estate Properties Held for Sale
The Company had one property classified as held for sale as of September 30, 2024 and two properties classified as held for sale as of December 31, 2023. The table below reflects the real estate assets classified as held for sale as of September 30, 2024 and December 31, 2023.

(Dollars in thousands)September 30, 2024December 31, 2023
Balance Sheet data:
Land$1,048 $1,576 
Building, improvements, and lease intangibles7,689 10,056 
8,737 11,632 
Accumulated depreciation(2,386)(4,166)
Real estate properties held for sale, net$6,351 $7,466 
v3.24.3
Debt, net
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Debt, net DEBT, NET
The table below details the Company's debt as of September 30, 2024 and December 31, 2023.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023Maturity Dates
Credit Facility:
Revolving Credit Facility$125,000 $50,000 3/26
A-3 Term Loan, net74,822 74,730 3/26
A-4 Term Loan, net124,607 124,522 3/28
A-5 Term Loan, net149,287 149,189 3/30
Mortgage Note Payable, net— 4,815 5/24
$473,716 $403,256 

Credit Facility
The Company's third amended and restated credit agreement, as amended (the "Credit Facility") is by and among
Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent. The Company amended the Credit Facility on October 16, 2024. See Note 14 – Subsequent Events on the Credit Facility refinancing.

As of September 30, 2024, the Credit Facility provided for a $150.0 million revolving credit facility (the "Revolving Credit Facility") and $350.0 million in term loans (the "Term Loans"). The Revolving Credit Facility was scheduled to mature on March 19, 2026 and included one 12-month option to extend the maturity date, subject to the satisfaction of certain conditions. The Term Loans include a seven-year term loan facility in the aggregate principal amount of $75.0 million (the "A-3 Term Loan"), which was scheduled to mature on March 29, 2026, a seven-year term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan"), which matures on March 19, 2028, and a seven-year and three-month term loan facility in the aggregate principal amount of $150.0 million (the "A-5 Term Loan") which matures on March 14, 2030. Loans under the Credit Facility are interest only with principal amounts due as of each facility's applicable maturity date. The Credit Facility allowed the Company to borrow, through the accordion feature, up to $700.0 million, including the ability to add and fund incremental term loans. The Company's material subsidiaries are guarantors of the obligations under the Credit Facility.

Amounts outstanding under the Revolving Credit Facility bore interest at a floating rate based on the Company's option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR plus 1.25% to 1.90% or (ii) a base rate plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. At September 30, 2024, the Company had $125.0 million outstanding under the Revolving Credit Facility with a weighted average interest rate of 6.58% and a borrowing capacity remaining of $25.0 million.

Amounts outstanding under the Term Loans will bear interest at a floating rate that is based, at the Company's option, on either (i) adjusted term SOFR or adjusted daily SOFR plus 1.65% to 2.30%, plus a simple SOFR adjustment equal to 0.10% per annum, or (ii) a base rate plus 0.65% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company has entered into interest rate swaps to fix the interest rates on the Term Loans. See Note 6 – Derivative Financial Instruments for more details on the interest rate swaps. At September 30, 2024, the Company had $350.0 million outstanding under the Term Loans with a fixed weighted average interest rate under the swaps of approximately 4.4%.
The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2024.

Mortgage Note Payable
During the three months ended June 30, 2024, the Company repaid its mortgage note payable totaling approximately $4.8 million.
v3.24.3
Derivative Financial Instruments
 9 Months Ended
Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments DERIVATIVE FINANCIAL INSTRUMENTS
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.

As of September 30, 2024, the Company had fifteen outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $350.0 million, which mature between 2026 and 2030, at the maturity dates of the associated term loans (see Note 5 – Debt, net).

Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023.
Asset Derivatives Fair Value atLiability Derivatives Fair Value at
(Dollars in thousands)September 30, 2024December 31, 2023Balance Sheet ClassificationSeptember 30, 2024December 31, 2023Balance Sheet Classification
Interest rate swaps$10,492 $16,417 Other assets, net$476 $— Other liabilities, net

The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive income ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings.

Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s Term Loans. During the next twelve months, the Company estimates that an additional $5.4 million will be reclassified from AOCI as a decrease to interest expense.
Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income
The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and nine months ended September 30, 2024 and 2023.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(Dollars in thousands)2024202320242023
Amount of unrealized (loss) gain recognized in OCI on derivative$(8,749)$8,691 $1,824 $13,593 
Amount of gain reclassified from AOCI into interest expense$(2,725)$(2,738)$(8,225)$(7,222)
Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded
$6,253 $4,641 $17,301 $12,773 

Tabular Disclosures of Offsetting Derivatives
The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of September 30, 2024 and December 31, 2023. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets.
Offsetting of Derivative Assets (as of September 30, 2024)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized AssetsGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$10,492 $— $10,492 $(476)$— $10,016 

Offsetting of Derivative Liabilities (as of September 30, 2024)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Liabilities in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$(476)$— $(476)$476 $— $— 

Offsetting of Derivative Assets (as of December 31, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized AssetsGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$16,417 $— $16,417 $— $— $16,417 
Offsetting of Derivative Liabilities (as of December 31, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Liabilities in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$— $— $— $— $— $— 

Credit-risk-related Contingent Features
As of September 30, 2024, the Company did not have any derivatives in a net liability position. As of September 30, 2024, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.
v3.24.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stockholders' Equity STOCKHOLDERS' EQUITY
Common Stock
The following table provides a reconciliation of the beginning and ending common stock balances for the nine months ended September 30, 2024 and for the year ended December 31, 2023:
(In thousands)Nine Months Ended
September 30, 2024		Year Ended
December 31, 2023
Balance, beginning of period27,61325,897
Issuance of common stock3131,385
Vested RSUs11— 
Restricted stock issued, net of withheld shares and forfeitures305331
Balance, end of period28,24227,613
_____________

ATM Program
The Company has an at-the-market offering program ("ATM Program"), with Piper Sandler & Co., Evercore Group L.L.C., Truist Securities, Inc., Regions Securities LLC, Robert W. Baird & Co. Incorporated, Fifth Third Securities, Inc. and Janney Montgomery Scott LLC, as sales agents (collectively, the “Agents”). Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $500.0 million. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the agreement and applicable law.

The Company's activity under the ATM Program during the nine months ended September 30, 2024 is detailed in the table below. As of September 30, 2024, the Company had approximately $426.3 million remaining that may be issued under the ATM Program.
Three Months Ended
September 30, 2024		Nine Months Ended
September 30, 2024
Shares issued (in thousands)
— 313
Net proceeds received (in millions)
— $7.5
Average gross sales price per share— $24.38
v3.24.3
Net Income (Loss) Per Common Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Income (Loss) Per Common Share NET INCOME (LOSS) PER COMMON SHARE
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and nine months ended September 30, 2024 and 2023, respectively.

Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands, except per share data)2024202320242023
Net income (loss)$1,749 $3,492 $(5,013)$3,147 
          Participating securities' share in earnings(756)(622)(2,075)(1,995)
Net income (loss), less participating securities' share in earnings$993 $2,870 $(7,088)$1,152 
Weighted average Common Shares outstanding
Weighted average Common Shares outstanding
28,168 26,823 27,910 26,411 
Unvested restricted shares
(1,508)(1,309)(1,431)(1,471)
Weighted average Common Shares outstanding–Basic26,660 25,514 26,479 24,940 
Weighted average Common Shares outstanding –Diluted
26,660 25,514 26,479 24,940 
Basic Net Income (Loss) Per Common Share$0.04 $0.11 $(0.27)$0.05 
Diluted Net Income (Loss) Per Common Share$0.04 $0.11 $(0.27)$0.05 
v3.24.3
Stock Incentive Plan
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock Incentive Plan STOCK INCENTIVE PLAN
Adoption of the 2024 Incentive Plan
The 2024 Incentive Plan, as amended, (the "Plan") was approved by our stockholders at our annual meeting on May 2, 2024. The Plan replaced our 2014 Incentive Plan, as amended, (the "2014 Plan") which had expired on March 31, 2024. The Plan, which will expire on March 4, 2034, implements several changes from the previous 2014 Plan:
•Freezes all awards under the 2014 Plan as of its expiration date;
•Removes the "evergreen provision" which allowed for the incremental automatic increase in the number of shares of common stock reserved for issuance under the Plan;
•Increases the number of shares of common stock authorized for issuance under the Plan to 1,150,000; and
•Expands the types of awards that may be awarded under the Plan.
A summary of restricted stock activity for the three and nine months ended September 30, 2024 and 2023 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(Dollars and shares in thousands)2024202320242023
Stock-based awards, beginning of period1,417 1,203 1,374 1,708 
Stock in lieu of compensation98 57 157 141 
Stock awards97 114 182 220 
   Total stock granted195 171 339 361 
Vested shares (1)
(51)— (152)(692)
Forfeited shares(1)— (1)(3)
Stock-based awards, end of period1,560 1,374 1,560 1,374 
Amortization expense (1)
$2,255 $1,898 $6,514 $17,936 
___________
(1) Amortization expense for the nine months ended September 30, 2023 included accelerated amortization totaling approximately $11.8 million recognized during the three months ended March 31, 2023, upon the passing of our former CEO and President. These shares vested during the three months ended June 30, 2023.
Restricted Stock Issuances
On January 12, 2024, pursuant to the 2014 Incentive Plan and the Third Amended and Restated Alignment of Interest Program, the Company granted 79,533 shares of restricted stock to its employees, in lieu of salary, that will cliff vest between three and eight years. Of the shares granted, 43,292 shares of restricted stock were granted in lieu of compensation from the program pool and 36,241 shares of restricted stock were awarded based on the restriction period elected from the plan pool. Also, on January 12, 2024, pursuant to the 2014 Incentive Plan and the Non-Executive Officer Incentive Program, the Company granted 10,159 shares of restricted stock to certain employees that will cliff vest in five years.

On May 2, 2024, pursuant to the 2024 Incentive Plan, the Company granted an aggregate of 22,070 shares of restricted stock to its Board of Directors, which will cliff vest in three years. On May 16, 2024, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted an aggregate of 24,887 shares of restricted stock to its Board of Directors, in lieu of fees, that will cliff vest in three years. Of the shares granted, 15,553 shares of restricted stock were granted in lieu of compensation from the program pool and 9,334 shares of restricted stock were awarded based on the restriction period elected from the plan pool. Also, on June 3, 2024, pursuant to the 2024 Incentive Plan, the Company granted 7,000 shares of restricted stock to an employee that will cliff vest in five years.

During the third quarter of 2024, pursuant to the 2024 Incentive Plan and the Fourth Amended and Restated Alignment of Interest Program, the Company granted an aggregate of 195,447 shares of restricted stock to its employees, in lieu of salary and bonus compensation, which will cliff vest between three and eight years. Of the shares granted, 98,111 shares of restricted stock were granted in lieu of compensation from the program pool and 97,336 shares of restricted stock were awarded based on the restriction period elected from the plan pool.

Compensation Programs under the 2024 Incentive Plan
The Company's various programs under the 2024 Incentive Plan have been amended during 2024 for various items, including: (i) allowing for the grant of RSUs and other types of awards other than restricted stock; (ii) limiting the maximum elective deferral percentage amount of salary and bonus to 50% to the acquisition of restricted stock for certain participants (previously 100%); and (iii) limiting the duration of the restriction period election depending on the retirement eligibility date per those participant's employment agreement. The deferral and restriction period limitations were effective beginning January 1, 2024 for salary and other compensation deferrals and are now effective for performance periods commencing on and after July 1, 2024 for cash bonus deferrals.

Restricted Stock Units
The Plan, and previous 2014 Plan, provide for the award of restricted stock units ("RSUs"). The Company historically granted long-term incentive awards to its executive officers which was comprised of restricted stock that vested in 8 years, based on backward-looking performance metrics. On January 2, 2024, the Board approved and adopted a new incentive compensation structure for its executive officers, including the issuance of time-based and performance-based RSUs with three-year forward-looking performance targets beginning with an initial performance period beginning July 1, 2023.

On January 2, 2024, the Company granted performance-based and time-based RSUs to its executive officers under the 2014 Incentive Plan and the Third Amended and Restated Executive Officer Incentive Program. These RSUs with a grant date value totaling $2.6 million are forward-looking with a three-year performance period beginning July 1, 2023. The performance-based RSUs were valued by independent specialists utilizing a Monte Carlo simulation to calculate the weighted average grant date fair values of $13.67 per share for the Absolute TSR units and $20.77 per share for the Relative TSR units. The grant date fair value of the Time-based TSR units was based on the Company's stock price on the grant date of $26.62. The combined weighted average grant date fair value of the RSUs granted was $19.24 per share. The following assumptions were used in valuing the performance-based RSUs:
Volatility25.0 %
Dividend assumption5.4 %
Expected term3 years
Risk-free rate4.3 %
Stock price (per share)$26.62 

A summary of the Company's RSU activity during the three and nine months ended September 30, 2024 and 2023, respectively, is included in the table below, as well as compensation expense recognized from the amortization of the value of RSUs over the applicable vesting periods.
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars and RSUs in thousands)2024202320242023
Restricted Stock Units, beginning of period134 — — — 
Absolute TSR Performance-based RSUs granted (1)
— — 57 — 
Relative TSR Performance-based RSUs granted (1)
— — 43 — 
Time-based RSUs granted (2)
— — 34 — 
Total RSUs granted— — 134 — 
Vested RSUs (2)
(11)— (11)— 
Restricted Stock Units, end of period123 — 123 — 
Amortization expense$242 $— $876 $— 
Grant Date Value Remaining at period end to be Amortized During the Performance Period$1,694 $— $1,694 $— 
______________
(1) The number of Performance-based RSUs granted were based on target levels. Actual number of shares granted will be based on performance at the end of the performance period which is June 30, 2026. The Performance-based RSUs, if earned, will vest at the end of the performance period.
(2) The number of Time-based RSUs granted were based on target levels. One-third of these RSUs will vest on each of June 30, 2025 and 2026. The first tranche of the 11,206 Time-Based RSUs was fully amortized as of June 30, 2024 and vested on July 1, 2024, the next business day after June 30, 2024.
v3.24.3
Other Assets, net
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Assets, net OTHER ASSETS, NET
Other assets, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are detailed in the table below.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023
Notes receivable, net of credit loss reserve$20,280 $30,775 
Straight-line rent receivables, net19,711 18,481 
Fair value of interest rate swaps10,492 16,417 
Leasing commissions, net3,920 2,312 
Sales-type lessor receivable3,017 3,028 
Financing lease right-of-use assets2,442 2,486 
Prepaid assets2,294 1,203 
Accounts receivable, net2,137 2,739 
Above-market intangible assets, net2,126 2,645 
Interest receivable, net1,798 1,906 
Operating lease right of use assets706 729 
Deferred financing costs, net312 471 
Other641 684 
$69,876 $83,876 
The Company's notes receivable mainly included:

•At September 30, 2024 and December 31, 2023, notes receivable included a term loan totaling $3.8 million and $6.0 million, respectively, secured by all assets and ownership interests in seven long-term acute care hospitals and one inpatient rehabilitation hospital owned by the borrower. The term loan will be repaid in equal monthly installments of $250,000 through the maturity date of December 31, 2025 and bears interest at 9% per annum.

•At September 30, 2024 and December 31, 2023, notes receivable included a term loan totaling $17.0 million, and a revolving credit facility with $6.3 million and $5.4 million drawn, respectively, secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. At September 30, 2024, the Company had an unfunded commitment of $2.2 million on the revolving credit facility and an unfunded commitment of up to $2.0 million on an advancing term loan facility. The term loan bears interest at 9% per annum, with interest only payments due initially and then equal monthly installments of principal payments due beginning March 31, 2025. The term loan facility matures on December 31, 2032. The revolving credit facility bears interest at 9% per annum and matures on December 31, 2025. The advancing term loan may be funded at the Company's discretion, and bears interest at 9% per annum on any amount funded, that may be used by the borrower to pay existing liabilities of co-borrowers. The term loan, the revolving credit facility and the additional commitment all include a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of each note.

In the second quarter of 2024, the Company determined that the collectability of the term loan and revolver loan was not reasonably assured. The tenant/borrower has experienced challenges with patient census and employee staffing, which has impacted cash flows from operations and the consistency of rent and interest payments to the Company. In the second quarter of 2024, the Company valued the notes based on its estimated value of the underlying collateral. As a result, in the second quarter of 2024, the Company recorded an $11.0 million credit loss reserve on its notes receivable with the tenant and reversed approximately $1.4 million of interest and placed the notes on non-accrual status. Changes in cash flows of the business, changes in market data, such as market multiples, and other relevant data may drive a change in the estimated value of the underlying collateral. At September 30, 2024, however, the Company did not believe that there were any material changes to warrant a change in the credit loss reserve recorded in the second quarter of 2024.

•At September 30, 2024 and December 31, 2023, notes receivable also included a $2.2 million and $2.3 million, respectively, revolving credit facility. This note will be repaid in equal monthly installments of $40,000 beginning on November 1, 2024, through the maturity date of April 1, 2027. The revolving credit facility bears interest at 9% per annum, as well as a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of the note.

•At September 30, 2024, notes receivable also included a $2.0 million construction mortgage loan with a developer which is secured by the land, improvements, and personal property. The mortgage loan, which bears interest at 10% per annum, will be interest only until the principal is due at the earlier of the completion and acquisition of the property, or August 15, 2027.

The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance. We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable. The VIEs that we have identified at September 30, 2024 are summarized in the table below.
Classification
Carrying Amount
(in thousands)
Maximum Exposure to Loss
(in thousands)
Note receivable (term loan)$3,750 $3,750 
Note receivable (revolving credit facility)$2,220 $2,220 
Note receivable (mortgage note)$2,000 $2,000 
Notes receivable (revolving credit facility and term loan), net of credit loss$12,310 $12,310 
v3.24.3
Other Liabilities, net
 9 Months Ended
Sep. 30, 2024
Other Liabilities Disclosure [Abstract]  
Other Liabilities, net OTHER LIABILITIES, NET
Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are detailed in the table below.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023
Prepaid rent$5,880 $5,378 
Security deposits2,951 3,765 
Below-market lease intangibles, net2,593 3,188 
Fair value of interest rate swaps476 — 
Financing lease liability3,265 3,277 
Operating lease liability766 775 
Other558 485 
$16,489 $16,868 
v3.24.3
Fair Value of Financial Instruments
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments FAIR VALUE OF FINANCIAL INSTRUMENTS
The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value.

Cash and cash equivalents and restricted cash - The carrying amount approximated the fair value. The fair value estimates were determined using level 1 inputs.

Notes and mortgage note receivable - The fair value was estimated using cash flow analyses, based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and were classified as level 2 inputs in the hierarchy. The fair value of notes receivable with one tenant was determined utilizing the fair value of the receivables' collateral, as the receivables are collateral-dependent, and were classified as level 3 inputs in the hierarchy.

Borrowings under our Credit Facility - The carrying amount approximated the fair value because the borrowings were based on variable market interest rates. The fair value estimates were determined using level 2 inputs.

Derivative financial instruments (Interest rate swaps) - The fair value was estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs were utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps were observable in active markets and were classified as level 2 inputs in the hierarchy.

Mortgage note payable - The fair value was estimated using cash flow analyses which were based on an assumed market rate of interest or at a rate consistent with the rates on mortgage notes assumed by the Company and were classified as level 2 inputs in the hierarchy.

The table below details the fair values and carrying values for our notes and mortgage note receivable, interest rate swaps, and mortgage note payable at September 30, 2024 and December 31, 2023, using level 2 and level 3 inputs.
September 30, 2024December 31, 2023
(Dollars in thousands)Carrying ValueFair ValueCarrying ValueFair Value
Notes and mortgage note receivable (Level 2)$7,970 $7,835 $8,340 $8,159 
Notes receivable, net of credit loss (1)
$12,310 $12,310 $22,435 $23,040 
Interest rate swap asset$10,492 $10,492 $16,417 $16,417 
Interest rate swap liability$476 $476 $— $— 
Mortgage note payable (principal amount)$— $— $4,821 $4,791 
___________________
(1) Calculated utilizing Level 3 inputs at September 30, 2024 and Level 2 inputs at December 31, 2023.
v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
Tenant Improvements
The Company may provide tenant improvement allowances in new or renewal leases for the purpose of refurbishing or renovating tenant space. The Company may also assume tenant improvement obligations included in leases acquired in its real estate acquisitions. As of September 30, 2024, the Company had approximately $26.0 million in commitments for tenant improvements. Six of these projects totaling $13.1 million, represent redevelopment projects of the buildings into different healthcare uses backed by long-term leases.

Capital Improvements
The Company has entered into contracts with various vendors for various capital improvement projects related to its portfolio. As of September 30, 2024, the Company had approximately $3.1 million in commitments for capital improvement projects. Six of these projects totaling $0.8 million, represent redevelopment projects of the buildings into different healthcare uses backed by long-term leases.

Legal Proceedings
The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's Consolidated Financial Statements.
v3.24.3
Subsequent Events
 9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS
Dividend Declared
On October 24, 2024, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.465 per share. The dividend is payable on November 22, 2024 to stockholders of record on November 8, 2024.

Credit Facility Refinancing
On October 16, 2024, the Company entered into a second amendment to the third amended and restated credit agreement (the "Amended Credit Facility") with a syndicate of lenders, under which Truist Bank serves as administrative agent. The Amended Credit Facility, among other things, (i) increased the Company's Revolving Credit Facility from $150.0 million to $400.0 million, (ii) extended the maturity date of the Revolving Credit Facility from March 19, 2026 to October 16, 2029, and (iii) lowered pricing on the Revolving Credit Facility by 10 to 30 basis points, depending on the Company's leverage ratio. Proceeds from the increased Revolving Credit Facility were used to repay the existing $75.0 million A-3 Term Loan which was scheduled to mature on March 29, 2026. In addition, amounts outstanding under the Revolving Credit Facility prior to the second Amendment will remain outstanding. Interest rate swaps previously entered into to fix the interest rates on the A-3 Term Loan will remain in place on the Revolving Credit Facility through their maturity on March 29, 2026.
v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net income (loss) $ 1,749 $ 3,492 $ (5,013) $ 3,147
v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Condensed Consolidated Financial Statements
Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes, including among others, estimates related to impairment assessments, purchase price allocations, valuation of properties held for sale, allowances for accounts and interest receivables, and valuation of financial instruments. Actual results may materially differ from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents and Restricted Cash
Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased.
Restricted Cash Restricted cash consisted of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments.
Rental Income and Interest Income
Rental Income
The primary source of revenue for the Company is generated through its leasing arrangements with its tenants which is accounted for under ASC Topic 842. The Company's rental income is based on contractual arrangements with its tenants. From the inception of a lease, if collection of substantially all of the lease payments is probable for a tenant, then rental income is recognized as earned over the life of the lease agreement on a straight-line basis. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue in amounts more or less than amounts currently due from tenants.

Interest Income
The Company's interest income is recognized based on contractual arrangements with its borrowers. The Company recognizes interest income on an accrual basis unless the Company determines that collectability of contractual amounts is not reasonably assured, at which point the interest on a given note is placed on non-accrual status and interest income is recognized on a cash basis.
Credit Losses
Credit Losses
Losses from Operating Lease Receivables
We assess the probability of collecting substantially all rents under our leases, on a tenant-by-tenant basis, based on several factors, including, payment and default history, financial strength of the tenant and/or guarantors, historical and operating trends of the property, and the value of the underlying collateral, if any. If management determines that collection of substantially all of a tenant's lease payments is not probable, we will revert to recognizing such lease payments at the lesser of cash collected, lease income reflected on a straight-line basis, or another systematic basis plus variable rent when it becomes accruable and will reverse any recorded receivables related to that lease. In the event that management subsequently determines collection of substantially all of that tenant's lease payments is probable, management will reinstate and record all such receivables for the lease in accordance with the lease terms. The Company also maintains a general allowance for its lease receivables that management has determined are probable of collection. Accounts receivable, straight-line rent and related allowances are included in Other assets on the Company's Condensed Consolidated Balance Sheets and any offsetting reduction in income is included in rental income on the Company's Condensed Statements of Operations.

Credit Losses on Loans and Interest Receivables
Historically, the Company has at times entered into loans with certain of its tenants for working capital or other needs. We consider our loans to be incidental to our main business of acquiring and leasing healthcare real estate. Credit losses on financial instruments are measured using an expected credit loss ("CECL") model in evaluating the collectability of notes receivable and other financial instruments. The CECL impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, that considers forecasts of future economic conditions in addition to information about past events and current conditions. Under the CECL model, the Company estimates credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument and is required to record a credit loss expense (or reversal) in each reporting period. The Company evaluates factors such as its historical credit loss experience with the borrower or similar financial assets, current economic conditions, current and expected future financial condition of the borrower, as well as payment history of the borrower, along with other relevant factors for each borrower or similar instruments. If a sale of the borrower's collateral, such as the underlying business or real estate, is expected to repay amounts due to the Company, the Company will also evaluate the underlying collateral in measuring any expected credit loss. The Company's financial instruments included in the scope of the CECL guidance are the principal balances of its tenant
notes receivable and its net investment in a sales-type lease which are included in Other assets on the Company's Condensed Consolidated Balance Sheets.
We made an accounting policy election to exclude interest receivables from the credit loss reserve model. The Company recognizes interest income on an accrual basis unless the Company has determined that collectability of contractual amounts is not reasonably assured, at which point the note is placed on non-accrual status and interest income is recognized on a cash basis. Subsequently, when collectability of contractual amounts is reasonably assured, management will resume the accrual basis.
Income Taxes
Income Taxes
The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes. No provision has been made for federal income taxes for the REIT; however, the Company has recorded income tax expense or benefit for the TRSs to the extent applicable. The Company intends at all times to qualify as a REIT under the Code. The Company must distribute at least 90% per annum of its REIT taxable income to its stockholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP) and meet other requirements to continue to qualify as a REIT.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
The Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280) on November 27, 2023. The provisions of this update generally include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit and loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that entity's with a single reportable segment provide all of the disclosures required by the amendments in this update. This update is effective for annual reporting periods beginning after December 31, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements other than the new disclosure requirements, as we operate under a single reportable segment. Compliance with these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
v3.24.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Company's Condensed
Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows:
 Balance as of September 30,
(Dollars in thousands)20242023
Cash and cash equivalents$2,836 $3,885 
Restricted cash— 1,048 
Cash, cash equivalents and restricted cash$2,836 $4,933 
Restrictions on Cash and Cash Equivalents The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Company's Condensed
Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows:
 Balance as of September 30,
(Dollars in thousands)20242023
Cash and cash equivalents$2,836 $3,885 
Restricted cash— 1,048 
Cash, cash equivalents and restricted cash$2,836 $4,933 
v3.24.3
Real Estate Investments (Tables)
 9 Months Ended
Sep. 30, 2024
Real Estate [Abstract]  
Schedule of Real Estate Property Investments The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables:
Property Type# of PropertiesGross Investment
(in thousands)
Medical Office Building96 $478,005 
Inpatient Rehabilitation Hospitals9 198,319 
Acute Inpatient Behavioral 5 130,535 
Specialty Centers37 117,989 
Physician Clinics31 94,965 
Surgical Centers and Hospitals9 58,474 
Behavioral Specialty Facilities9 45,067 
Long-term Acute Care Hospitals2 21,484 
Total198 $1,144,838 
State# of PropertiesGross Investment
(in thousands)
Texas17 $185,738 
Illinois18 132,814 
Ohio26 115,313 
Florida25 110,114 
Pennsylvania16 67,483 
All Others96 533,376 
Total198 $1,144,838 

Primary Tenant# of PropertiesGross Investment
(in thousands)
Lifepoint Health
5 $86,682 
US HealthVest3 77,964 
All Others (less than 4%)190 980,192 
Total198 $1,144,838 
v3.24.3
Real Estate Leases (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases
Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of September 30, 2024, are as follows (in thousands):
2024 (three months ended December 31)$25,911 
202599,363 
202690,380 
202782,587 
202875,773 
2029 and thereafter411,035 
$785,049 
Schedule of Lease Receivables Future lease payments due to the Company under this lease for the years ending December 31, as of September 30, 2024, are as follows (in thousands):
2024 (three months ended December 31)$88 
2025356 
2026367 
2027378 
2028389 
2029 and thereafter4,821 
Total undiscounted lease receivable6,399 
Discount(3,382)
Lease receivable$3,017 
Schedule of Operating Lease Payments The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):
OperatingFinancing
2024 (three months ended December 31)$11 $37 
202544 154 
202644 154 
202745 154 
202846 154 
2029 and thereafter1,102 6,802 
Total undiscounted lease payments1,292 7,455 
Discount(526)(4,190)
Lease liabilities$766 $3,265 
Schedule of Finance Lease Payments The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):
OperatingFinancing
2024 (three months ended December 31)$11 $37 
202544 154 
202644 154 
202745 154 
202846 154 
2029 and thereafter1,102 6,802 
Total undiscounted lease payments1,292 7,455 
Discount(526)(4,190)
Lease liabilities$766 $3,265 
Schedule of Ground Leases
The following table discloses other information regarding the ground leases.
Three Months Ended
September 30,
20242023
Operating leases:
Weighted-average remaining lease term in years (including renewal options)34.235.4
Weighted-average discount rate4.0 %4.0 %
Financing leases:
Weighted-average remaining lease term in years (including renewal options)39.140.1
Weighted-average discount rate4.3 %4.3 %
v3.24.3
Real Estate Acquisitions, Disposition, And Assets Held For Sale (Tables)
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Property Acquisitions
The following table summarizes our property acquisitions for the nine months ended September 30, 2024:
Location
Property
Type (1)
Number of PropertiesDate
Acquired		Purchase
Price		Cash
Consideration		Real Estate
Other (2)
Square Footage
(000's)(000's)(000's)(000's)
New Bedford, MALTACH11/31/24$6,500 $6,540 $6,547 $(7)70,657 
Elkton, MDMOB13/25/244,500 4,578 4,757 (179)19,656 
Bemidji, MNMOB23/29/2423,200 23,179 23,375 (196)74,700 
San Antonio, TXIRF14/16/2423,500 23,547 23,547 — 38,009 
Camp Hill, PAPC17/22/246,200 6,308 6,323 (15)20,400 
$63,900 $64,152 $64,549 $(397)223,422 
(1) LTACH - Long-term Acute Care Hospital; MOB - Medical Office Building; IRF - Inpatient Rehabilitation Facility; PC - Physician Clinic
(2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition
Schedule of Assets Acquired and Liabilities Assumed
The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the nine months ended September 30, 2024:
Relative
Fair Value		Estimated
Useful Life
(in thousands)(in years)
Land and land improvements$7,659 9.2
Building and building improvements53,116 35.0
Intangibles:
In-place lease intangibles3,774 3.7
Above-market lease intangibles121 5.0
Below-market lease intangibles(275)2.0
Total intangibles3,620 
Accounts payable, accrued liabilities and other liabilities assumed(194)
Accounts receivable and other assets acquired48 
Prorated rent, interest and operating expense reimbursement amounts collected(97)
Total cash consideration$64,152 
Schedule of Assets and Liabilities Classified as Held for Sale The table below reflects the real estate assets classified as held for sale as of September 30, 2024 and December 31, 2023.
(Dollars in thousands)September 30, 2024December 31, 2023
Balance Sheet data:
Land$1,048 $1,576 
Building, improvements, and lease intangibles7,689 10,056 
8,737 11,632 
Accumulated depreciation(2,386)(4,166)
Real estate properties held for sale, net$6,351 $7,466 
v3.24.3
Debt, net (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
The table below details the Company's debt as of September 30, 2024 and December 31, 2023.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023Maturity Dates
Credit Facility:
Revolving Credit Facility$125,000 $50,000 3/26
A-3 Term Loan, net74,822 74,730 3/26
A-4 Term Loan, net124,607 124,522 3/28
A-5 Term Loan, net149,287 149,189 3/30
Mortgage Note Payable, net— 4,815 5/24
$473,716 $403,256 
v3.24.3
Derivative Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Derivative Instruments on Balance Sheet
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023.
Asset Derivatives Fair Value atLiability Derivatives Fair Value at
(Dollars in thousands)September 30, 2024December 31, 2023Balance Sheet ClassificationSeptember 30, 2024December 31, 2023Balance Sheet Classification
Interest rate swaps$10,492 $16,417 Other assets, net$476 $— Other liabilities, net
The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets.
Offsetting of Derivative Assets (as of September 30, 2024)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized AssetsGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$10,492 $— $10,492 $(476)$— $10,016 

Offsetting of Derivative Liabilities (as of September 30, 2024)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Liabilities in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$(476)$— $(476)$476 $— $— 

Offsetting of Derivative Assets (as of December 31, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized AssetsGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Assets in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$16,417 $— $16,417 $— $— $16,417 
Offsetting of Derivative Liabilities (as of December 31, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands)Gross Amounts of Recognized LiabilitiesGross Amounts Offset in the Condensed Consolidated Balance SheetNet Amounts of Liabilities in the Condensed Consolidated Balance SheetsFinancial InstrumentsCash Collateral ReceivedNet Amount
Derivatives$— $— $— $— $— $— 
Schedule of Cash Flow Hedging
The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and nine months ended September 30, 2024 and 2023.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(Dollars in thousands)2024202320242023
Amount of unrealized (loss) gain recognized in OCI on derivative$(8,749)$8,691 $1,824 $13,593 
Amount of gain reclassified from AOCI into interest expense$(2,725)$(2,738)$(8,225)$(7,222)
Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded
$6,253 $4,641 $17,301 $12,773 
v3.24.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Reconciliation of Common Stock
The following table provides a reconciliation of the beginning and ending common stock balances for the nine months ended September 30, 2024 and for the year ended December 31, 2023:
(In thousands)Nine Months Ended
September 30, 2024		Year Ended
December 31, 2023
Balance, beginning of period27,61325,897
Issuance of common stock3131,385
Vested RSUs11— 
Restricted stock issued, net of withheld shares and forfeitures305331
Balance, end of period28,24227,613
_____________
Schedule of ATM Program As of September 30, 2024, the Company had approximately $426.3 million remaining that may be issued under the ATM Program.
Three Months Ended
September 30, 2024		Nine Months Ended
September 30, 2024
Shares issued (in thousands)
— 313
Net proceeds received (in millions)
— $7.5
Average gross sales price per share— $24.38
v3.24.3
Net Income (Loss) Per Common Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Net Income (Loss) Per Common Share
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and nine months ended September 30, 2024 and 2023, respectively.

Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands, except per share data)2024202320242023
Net income (loss)$1,749 $3,492 $(5,013)$3,147 
          Participating securities' share in earnings(756)(622)(2,075)(1,995)
Net income (loss), less participating securities' share in earnings$993 $2,870 $(7,088)$1,152 
Weighted average Common Shares outstanding
Weighted average Common Shares outstanding
28,168 26,823 27,910 26,411 
Unvested restricted shares
(1,508)(1,309)(1,431)(1,471)
Weighted average Common Shares outstanding–Basic26,660 25,514 26,479 24,940 
Weighted average Common Shares outstanding –Diluted
26,660 25,514 26,479 24,940 
Basic Net Income (Loss) Per Common Share$0.04 $0.11 $(0.27)$0.05 
Diluted Net Income (Loss) Per Common Share$0.04 $0.11 $(0.27)$0.05 
v3.24.3
Stock Incentive Plan (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Nonvested Restricted Stock Activity
A summary of restricted stock activity for the three and nine months ended September 30, 2024 and 2023 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(Dollars and shares in thousands)2024202320242023
Stock-based awards, beginning of period1,417 1,203 1,374 1,708 
Stock in lieu of compensation98 57 157 141 
Stock awards97 114 182 220 
   Total stock granted195 171 339 361 
Vested shares (1)
(51)— (152)(692)
Forfeited shares(1)— (1)(3)
Stock-based awards, end of period1,560 1,374 1,560 1,374 
Amortization expense (1)
$2,255 $1,898 $6,514 $17,936 
___________
(1) Amortization expense for the nine months ended September 30, 2023 included accelerated amortization totaling approximately $11.8 million recognized during the three months ended March 31, 2023, upon the passing of our former CEO and President. These shares vested during the three months ended June 30, 2023.
A summary of the Company's RSU activity during the three and nine months ended September 30, 2024 and 2023, respectively, is included in the table below, as well as compensation expense recognized from the amortization of the value of RSUs over the applicable vesting periods.
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars and RSUs in thousands)2024202320242023
Restricted Stock Units, beginning of period134 — — — 
Absolute TSR Performance-based RSUs granted (1)
— — 57 — 
Relative TSR Performance-based RSUs granted (1)
— — 43 — 
Time-based RSUs granted (2)
— — 34 — 
Total RSUs granted— — 134 — 
Vested RSUs (2)
(11)— (11)— 
Restricted Stock Units, end of period123 — 123 — 
Amortization expense$242 $— $876 $— 
Grant Date Value Remaining at period end to be Amortized During the Performance Period$1,694 $— $1,694 $— 
______________
(1) The number of Performance-based RSUs granted were based on target levels. Actual number of shares granted will be based on performance at the end of the performance period which is June 30, 2026. The Performance-based RSUs, if earned, will vest at the end of the performance period.
(2) The number of Time-based RSUs granted were based on target levels. One-third of these RSUs will vest on each of June 30, 2025 and 2026. The first tranche of the 11,206 Time-Based RSUs was fully amortized as of June 30, 2024 and vested on July 1, 2024, the next business day after June 30, 2024.
Schedule of Valuation Assumptions The following assumptions were used in valuing the performance-based RSUs:
Volatility25.0 %
Dividend assumption5.4 %
Expected term3 years
Risk-free rate4.3 %
Stock price (per share)$26.62 
v3.24.3
Other Assets, net (Tables)
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Assets
Other assets, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are detailed in the table below.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023
Notes receivable, net of credit loss reserve$20,280 $30,775 
Straight-line rent receivables, net19,711 18,481 
Fair value of interest rate swaps10,492 16,417 
Leasing commissions, net3,920 2,312 
Sales-type lessor receivable3,017 3,028 
Financing lease right-of-use assets2,442 2,486 
Prepaid assets2,294 1,203 
Accounts receivable, net2,137 2,739 
Above-market intangible assets, net2,126 2,645 
Interest receivable, net1,798 1,906 
Operating lease right of use assets706 729 
Deferred financing costs, net312 471 
Other641 684 
$69,876 $83,876 
Schedule of VIEs The VIEs that we have identified at September 30, 2024 are summarized in the table below.
Classification
Carrying Amount
(in thousands)
Maximum Exposure to Loss
(in thousands)
Note receivable (term loan)$3,750 $3,750 
Note receivable (revolving credit facility)$2,220 $2,220 
Note receivable (mortgage note)$2,000 $2,000 
Notes receivable (revolving credit facility and term loan), net of credit loss$12,310 $12,310 
v3.24.3
Other Liabilities, net (Tables)
 9 Months Ended
Sep. 30, 2024
Other Liabilities Disclosure [Abstract]  
Schedule of Other Liabilities
Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 are detailed in the table below.
Balance as of
(Dollars in thousands)September 30, 2024December 31, 2023
Prepaid rent$5,880 $5,378 
Security deposits2,951 3,765 
Below-market lease intangibles, net2,593 3,188 
Fair value of interest rate swaps476 — 
Financing lease liability3,265 3,277 
Operating lease liability766 775 
Other558 485 
$16,489 $16,868 
v3.24.3
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, by Balance Sheet Grouping
The table below details the fair values and carrying values for our notes and mortgage note receivable, interest rate swaps, and mortgage note payable at September 30, 2024 and December 31, 2023, using level 2 and level 3 inputs.
September 30, 2024December 31, 2023
(Dollars in thousands)Carrying ValueFair ValueCarrying ValueFair Value
Notes and mortgage note receivable (Level 2)$7,970 $7,835 $8,340 $8,159 
Notes receivable, net of credit loss (1)
$12,310 $12,310 $22,435 $23,040 
Interest rate swap asset$10,492 $10,492 $16,417 $16,417 
Interest rate swap liability$476 $476 $— $— 
Mortgage note payable (principal amount)$— $— $4,821 $4,791 
___________________
(1) Calculated utilizing Level 3 inputs at September 30, 2024 and Level 2 inputs at December 31, 2023.
v3.24.3
Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands, ft² in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
ft²
realEstateProperty
state
segment
Dec. 31, 2023
USD ($)
realEstateProperty
Accounting Policies [Abstract]    
Total real estate properties | $ $ 1,144,838  
Number of real estate properties | realEstateProperty 198  
Number of properties held for investment in financing lease | realEstateProperty 1  
Sales-type lessor receivable | $ $ 3,017 $ 3,028
Number of properties held for sale | realEstateProperty 1 2
Properties held for sale | $ $ 6,400  
Number of states | state 35  
Area of real estate property (in square feet) | ft² 4.4  
Percentage leased 91.30%  
Remaining lease term 6 years 9 months 18 days  
Number of reportable segments | segment 1  
v3.24.3
Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]        
Cash and cash equivalents $ 2,836 $ 3,491 $ 3,885  
Restricted cash 0 1,142 1,048  
Cash, cash equivalents and restricted cash $ 2,836 $ 4,633 $ 4,933 $ 12,068
v3.24.3
Real Estate Investments - Additional Information (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
realEstateProperty
Dec. 31, 2023
USD ($)
realEstateProperty
Real Estate Properties [Line Items]    
Total real estate properties $ 1,144,838  
Number of real estate properties | realEstateProperty 198  
Number of properties held for investment in financing lease | realEstateProperty 1  
Sales-type lessor receivable $ 3,017 $ 3,028
Number of properties held for sale | realEstateProperty 1 2
Properties held for sale $ 6,400  
Held for sale    
Real Estate Properties [Line Items]    
Properties held for sale $ 6,400  
v3.24.3
Real Estate Investments - Schedule of Real Estate Property Investments (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
realEstateProperty
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 198
Total real estate properties | $ $ 1,144,838
Lifepoint Health  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 5
Total real estate properties | $ $ 86,682
US HealthVest  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 3
Total real estate properties | $ $ 77,964
All Others (less than 4%)  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 190
Total real estate properties | $ $ 980,192
Texas  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 17
Total real estate properties | $ $ 185,738
Illinois  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 18
Total real estate properties | $ $ 132,814
Ohio  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 26
Total real estate properties | $ $ 115,313
Florida  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 25
Total real estate properties | $ $ 110,114
Pennsylvania  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 16
Total real estate properties | $ $ 67,483
All Others  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 96
Total real estate properties | $ $ 533,376
Medical Office Building  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 96
Total real estate properties | $ $ 478,005
Inpatient Rehabilitation Hospitals  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 9
Total real estate properties | $ $ 198,319
Acute Inpatient Behavioral  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 5
Total real estate properties | $ $ 130,535
Specialty Centers  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 37
Total real estate properties | $ $ 117,989
Physician Clinics  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 31
Total real estate properties | $ $ 94,965
Surgical Centers and Hospitals  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 9
Total real estate properties | $ $ 58,474
Behavioral Specialty Facilities  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 9
Total real estate properties | $ $ 45,067
Long-term Acute Care Hospitals  
Real Estate Properties [Line Items]  
Number of real estate properties | realEstateProperty 2
Total real estate properties | $ $ 21,484
v3.24.3
Real Estate Leases - Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Leases [Abstract]  
2024 (three months ended December 31) $ 25,911
2025 99,363
2026 90,380
2027 82,587
2028 75,773
2029 and thereafter 411,035
Total $ 785,049
v3.24.3
Real Estate Leases - Additional Information (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
realEstateProperty
lease
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
realEstateProperty
lease
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Concentration Risk [Line Items]          
Straight line rent $ 700 $ 400 $ 1,230 $ 2,180  
Real estate investment property, net $ 902,716   $ 902,716   $ 849,437
Number of real estate properties | realEstateProperty 198   198    
Number of properties held for investment in financing lease | realEstateProperty 1   1    
Sales-type lessor receivable $ 3,017   $ 3,017   $ 3,028
Interest income $ 100 $ 100 $ 200 $ 200  
Number of operating leases | lease 4   4    
Number of finance leases | lease 2   2    
Eleven Real Estate Property          
Concentration Risk [Line Items]          
Real estate investment property, net $ 32,900   $ 32,900    
Number of real estate properties | realEstateProperty 10   10    
v3.24.3
Real Estate Leases - Lease Receivables (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Leases [Abstract]    
2024 (three months ended December 31) $ 88  
2025 356  
2026 367  
2027 378  
2028 389  
2029 and thereafter 4,821  
Total undiscounted lease receivable 6,399  
Discount (3,382)  
Sales-type lessor receivable $ 3,017 $ 3,028
v3.24.3
Real Estate Leases - Future Lease Payments Under Non-prepaid Ground Leases (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Operating    
2024 (three months ended December 31) $ 11  
2025 44  
2026 44  
2027 45  
2028 46  
2029 and thereafter 1,102  
Total undiscounted lease payments 1,292  
Discount (526)  
Lease liabilities 766 $ 775
Financing    
2024 (three months ended December 31) 37  
2025 154  
2026 154  
2027 154  
2028 154  
2029 and thereafter 6,802  
Total undiscounted lease payments 7,455  
Discount (4,190)  
Lease liabilities $ 3,265 $ 3,277
v3.24.3
Real Estate Leases - Ground Leases (Details)
Sep. 30, 2024
Sep. 30, 2023
Operating leases:    
Weighted-average remaining lease term in years (including renewal options) 34 years 2 months 12 days 35 years 4 months 24 days
Weighted-average discount rate 4.00% 4.00%
Financing leases:    
Weighted-average remaining lease term in years (including renewal options) 39 years 1 month 6 days 40 years 1 month 6 days
Weighted-average discount rate 4.30% 4.30%
v3.24.3
Real Estate Acquisitions, Disposition, And Assets Held For Sale - Additional Information (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
ft²
realEstateProperty
Jun. 30, 2024
realEstateProperty
Mar. 31, 2024
transaction
realEstateProperty
Sep. 30, 2024
USD ($)
ft²
realEstateProperty
Dec. 31, 2023
realEstateProperty
Business Acquisition [Line Items]          
Area of real estate property (in square feet) | ft² 4,400,000     4,400,000  
Number of properties held for sale | realEstateProperty 1     1 2
Disposed of by sale | Surgical Center          
Business Acquisition [Line Items]          
Area of real estate property (in square feet) | ft² 11,200     11,200  
Proceeds from sale of property $ 1,000        
Acquisitions Of Properties During Q3 2024          
Business Acquisition [Line Items]          
Number of real estate properties acquired | realEstateProperty 1        
Percentage of properties that were leased at acquisition (in percent) 100.00%        
Pro forma information, revenue of acquiree since acquisition date, actual $ 116        
Pro forma information, earnings or loss of acquiree since acquisition date, actual 26        
Transaction costs $ 123        
Acquisitions Of Properties During Q2 2024          
Business Acquisition [Line Items]          
Number of real estate properties acquired | realEstateProperty   1      
Percentage of properties that were leased at acquisition (in percent)   100.00%      
Pro forma information, revenue of acquiree since acquisition date, actual       $ 1,100  
Pro forma information, earnings or loss of acquiree since acquisition date, actual       800  
Transaction costs       47  
Acquisitions Of Properties During Q1 2024          
Business Acquisition [Line Items]          
Number of real estate properties acquired | realEstateProperty     4    
Percentage of properties that were leased at acquisition (in percent)     98.60%    
Pro forma information, revenue of acquiree since acquisition date, actual       2,100  
Pro forma information, earnings or loss of acquiree since acquisition date, actual       1,000  
Transaction costs       $ 300  
Number of transactions | transaction     3    
v3.24.3
Real Estate Acquisitions, Disposition, And Assets Held For Sale - Summary of Property Acquisitions (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
ft²
realEstateProperty
Jun. 30, 2024
realEstateProperty
Mar. 31, 2024
realEstateProperty
Sep. 30, 2024
USD ($)
ft²
realEstateProperty
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Square footage (in square feet) | ft² 4,400,000     4,400,000
Acquisitions Of Properties During Q1 2024        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty     4  
Acquisitions Of Properties During Q1 2024 | New Bedford, MA        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty       1
Purchase Price       $ 6,500
Cash Consideration       6,540
Real Estate $ 6,547     6,547
Other       $ (7)
Square footage (in square feet) | ft² 70,657     70,657
Acquisitions Of Properties During Q1 2024 | Elkton, MD        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty       1
Purchase Price       $ 4,500
Cash Consideration       4,578
Real Estate $ 4,757     4,757
Other       $ (179)
Square footage (in square feet) | ft² 19,656     19,656
Acquisitions Of Properties During Q1 2024 | Bemidji, MN        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty       2
Purchase Price       $ 23,200
Cash Consideration       23,179
Real Estate $ 23,375     23,375
Other       $ (196)
Square footage (in square feet) | ft² 74,700     74,700
Acquisitions Of Properties During Q2 2024        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty   1    
Acquisitions Of Properties During Q2 2024 | San Antonio, TX        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty       1
Purchase Price       $ 23,500
Cash Consideration       23,547
Real Estate $ 23,547     23,547
Other       $ 0
Square footage (in square feet) | ft² 38,009     38,009
Acquisitions Of Properties During Q3 2024        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty 1      
Acquisitions Of Properties During Q3 2024 | Camp Hill, PA        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of Properties | realEstateProperty       1
Purchase Price       $ 6,200
Cash Consideration       6,308
Real Estate $ 6,323     6,323
Other       $ (15)
Square footage (in square feet) | ft² 20,400     20,400
Acquisitions Of Properties During 2024        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Purchase Price       $ 63,900
Cash Consideration       64,152
Real Estate $ 64,549     64,549
Other       $ (397)
Square footage (in square feet) | ft² 223,422     223,422
v3.24.3
Real Estate Acquisitions, Disposition, And Assets Held For Sale - Assets Acquired and Liabilities Assumed (Details) - Series of Individually Immaterial Asset Acquisitions
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Business Acquisition [Line Items]  
Land and land improvements $ 7,659
Building and building improvements 53,116
Intangibles:  
Below-market lease intangibles $ (275)
Below market lease useful life (in years) 2 years
Total intangibles $ 3,620
Accounts payable, accrued liabilities and other liabilities assumed (194)
Accounts receivable and other assets acquired 48
Prorated rent, interest and operating expense reimbursement amounts collected (97)
Total cash consideration 64,152
In-place lease intangibles  
Intangibles:  
Lease intangibles $ 3,774
Intangibles useful life (in years) 3 years 8 months 12 days
Above-market lease intangibles  
Intangibles:  
Lease intangibles $ 121
Intangibles useful life (in years) 5 years
Land and land improvements  
Business Acquisition [Line Items]  
Estimated useful life (in years) 9 years 2 months 12 days
Building and building improvements  
Business Acquisition [Line Items]  
Estimated useful life (in years) 35 years
v3.24.3
Real Estate Acquisitions, Disposition, And Assets Held For Sale - Schedule of Assets and Liabilities Classified as Held for Sale (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Real estate properties held for sale, net $ 6,400  
Held for sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Real estate properties held for sale, net 6,400  
Held for sale | Real estate properties held for sale, net    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Real estate assets held for sale, gross 8,737 $ 11,632
Accumulated depreciation (2,386) (4,166)
Real estate properties held for sale, net 6,351 7,466
Held for sale | Land    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Real estate assets held for sale, gross 1,048 1,576
Held for sale | Building, improvements, and lease intangibles    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Real estate assets held for sale, gross $ 7,689 $ 10,056
v3.24.3
Debt, net - Schedule of Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Debt, net $ 473,716 $ 403,256
Term Loan | Third Amended And Restated Credit Facility    
Debt Instrument [Line Items]    
Debt, net 350,000  
Mortgage Note Payable, net    
Debt Instrument [Line Items]    
Debt, net 0 4,815
Revolving Credit Facility | Line of Credit | Third Amended And Restated Credit Facility    
Debt Instrument [Line Items]    
Debt, net 125,000 50,000
A-3 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility    
Debt Instrument [Line Items]    
Debt, net 74,822 74,730
A-4 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility    
Debt Instrument [Line Items]    
Debt, net 124,607 124,522
A-5 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility    
Debt Instrument [Line Items]    
Debt, net $ 149,287 $ 149,189
v3.24.3
Debt, net - Additional Information (Details)
 9 Months Ended
Sep. 30, 2024
USD ($)
option
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Line of Credit Facility [Line Items]      
Debt, net $ 473,716,000   $ 403,256,000
Mortgage Note Payable, net      
Line of Credit Facility [Line Items]      
Debt, net 0   4,815,000
Debt instrument, balloon payment to be paid   $ 4,800,000  
Third Amended And Restated Credit Facility | Term Loan      
Line of Credit Facility [Line Items]      
Debt, net $ 350,000,000.0    
Weighted average interest rate percentage 4.40%    
Third Amended And Restated Credit Facility | Term Loan | Secured Overnight Financing Rate (SOFR) | Minimum      
Line of Credit Facility [Line Items]      
Variable rate percentage 1.65%    
Third Amended And Restated Credit Facility | Term Loan | Secured Overnight Financing Rate (SOFR) | Maximum      
Line of Credit Facility [Line Items]      
Variable rate percentage 2.30%    
Third Amended And Restated Credit Facility | Term Loan | Base Rate | Minimum      
Line of Credit Facility [Line Items]      
Variable rate percentage 0.65%    
Third Amended And Restated Credit Facility | Term Loan | Base Rate | Maximum      
Line of Credit Facility [Line Items]      
Variable rate percentage 1.30%    
Third Amended And Restated Credit Facility | Term Loan | Simple SOFR | Maximum      
Line of Credit Facility [Line Items]      
Variable rate percentage 0.10%    
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity $ 150,000,000.0    
Number of options to extend | option 1    
Length of extension 12 months    
Debt, net $ 125,000,000   50,000,000
Weighted average interest rate percentage 6.58%    
Remaining borrowing capacity $ 25,000,000.0    
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) | Minimum      
Line of Credit Facility [Line Items]      
Variable rate percentage 1.25%    
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) | Maximum      
Line of Credit Facility [Line Items]      
Variable rate percentage 1.90%    
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | Base Rate | Minimum      
Line of Credit Facility [Line Items]      
Variable rate percentage 0.25%    
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | Base Rate | Maximum      
Line of Credit Facility [Line Items]      
Variable rate percentage 0.90%    
Third Amended And Restated Credit Facility | Term Loan | Line of Credit      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity $ 350,000,000.0    
Third Amended And Restated Credit Facility | A-3 Term Loan, net | Term Loan      
Line of Credit Facility [Line Items]      
Debt term (in years) 7 years    
Face amount $ 75,000,000.0    
Debt, net $ 74,822,000   74,730,000
Third Amended And Restated Credit Facility | A-4 Term Loan, net | Term Loan      
Line of Credit Facility [Line Items]      
Debt term (in years) 7 years    
Face amount $ 125,000,000    
Debt, net $ 124,607,000   124,522,000
Third Amended And Restated Credit Facility | A-5 Term Loan, net | Term Loan      
Line of Credit Facility [Line Items]      
Debt term (in years) 7 years 3 months    
Face amount $ 150,000,000    
Debt, net 149,287,000   $ 149,189,000
Third Amended And Restated Credit Facility | Credit Facility, Accordion Feature      
Line of Credit Facility [Line Items]      
Maximum borrowing capacity $ 700,000,000    
Third Amended And Restated Credit Facility | Revolving Credit Facility, Unused Borrowing Capacity Rate 1 | Line of Credit      
Line of Credit Facility [Line Items]      
Unused borrowing commitment fee percentage 0.20%    
Percentage of borrowing capacity outstanding 33.30%    
Third Amended And Restated Credit Facility | Revolving Credit Facility, Unused Borrowing Capacity Rate 2 | Line of Credit      
Line of Credit Facility [Line Items]      
Unused borrowing commitment fee percentage 0.25%    
Percentage of borrowing capacity outstanding 33.30%    
v3.24.3
Derivative Financial Instruments - Additional Information (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
derivative_instrument
Derivative [Line Items]  
Cash flow hedges reclassified to interest expense $ 5.4
Cash Flow Hedging | Interest Rate Contract  
Derivative [Line Items]  
Number outstanding interest rate derivatives | derivative_instrument 15
Notional amount $ 350.0
v3.24.3
Derivative Financial Instruments - Schedule of Fair Value Balance Sheet (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Derivatives, Fair Value [Line Items]    
Interest rate swap asset $ 10,492 $ 16,417
Interest rate swap liability $ 476 $ 0
Derivative asset, statement of financial position [Extensible Enumeration] Other assets, net Other assets, net
Derivative liability, statement of financial position [Extensible Enumeration] Other liabilities, net Other liabilities, net
Cash Flow Hedging | Interest rate swaps | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Interest rate swap asset $ 10,492 $ 16,417
Interest rate swap liability $ 476 $ 0
v3.24.3
Derivative Financial Instruments - Schedule of Cash Flow Hedging (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, gain (loss), statement of income or comprehensive income [Extensible Enumeration] Interest Expense, Nonoperating Interest Expense, Nonoperating Interest Expense, Nonoperating Interest Expense, Nonoperating
Interest Rate Contract | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of unrealized (loss) gain recognized in OCI on derivative $ (8,749) $ 8,691 $ 1,824 $ 13,593
Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded 6,253 4,641 17,301 12,773
Interest Rate Contract | Cash Flow Hedging | Interest Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain reclassified from AOCI into interest expense $ (2,725) $ (2,738) $ (8,225) $ (7,222)
v3.24.3
Derivative Financial Instruments - Schedule of Offsetting of Derivative Assets and Liability (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Derivative Asset [Abstract]    
Gross Amounts of Recognized Assets $ 10,492 $ 16,417
Gross Amounts Offset in the Condensed Consolidated Balance Sheet 0 0
Net Amounts of Assets in the Condensed Consolidated Balance Sheets 10,492 16,417
Gross amounts not offset in the condensed consolidated balance sheets, financial instruments (476) 0
Gross amounts not offset in the condensed consolidated balance sheets, net amount 0 0
Gross amounts not offset in the condensed consolidated balance sheets, cash collateral received 10,016 16,417
Derivative Liability [Abstract]    
Gross Amounts of Recognized Liabilities (476) 0
Gross Amounts Offset in the Condensed Consolidated Balance Sheet 0 0
Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets (476) 0
Gross amounts not offset in the condensed consolidated balance sheets, financial instruments 476 0
Gross amounts not offset in the condensed consolidated balance sheets, cash collateral received 0 0
Gross amounts not offset in the condensed consolidated balance sheets, net amount $ 0 $ 0
v3.24.3
Stockholders' Equity - Schedule of Reconciliation of Common Stock (Details) - shares
shares in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of period (in shares) 27,613 25,897
Issuance of common stock (in shares) 313 1,385
Restricted stock issued (in shares) 305 331
Balance, end of period (in shares) 28,242 27,613
Vested RSUs (in shares) 11 0
v3.24.3
Stockholders' Equity - Additional Information (Details) - At The Market Offering Program - Common Stock
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
Subsidiary, Sale of Stock [Line Items]  
Value of shares authorized $ 500.0
Shares available for issuance $ 426.3
v3.24.3
Stockholders' Equity - Schedule of ATM Program (Details) - Common Stock - At The Market Offering Program - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Class of Stock [Line Items]    
Shares issued (in shares) 0 313
Net proceeds received $ 0.0 $ 7.5
Average gross sales price per share (in dollars per share) $ 0 $ 24.38
v3.24.3
Net Income (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Earnings Per Share [Abstract]        
Net income (loss) $ 1,749 $ 3,492 $ (5,013) $ 3,147
Participating securities' share in earnings (756) (622) (2,075) (1,995)
Net income (loss), less participating securities' share in earnings $ 993 $ 2,870 $ (7,088) $ 1,152
Weighted average Common Shares outstanding        
Weighted average common shares outstanding (in shares) 28,168 26,823 27,910 26,411
Unvested restricted shares (in shares) (1,508) (1,309) (1,431) (1,471)
Weighted average common shares outstanding – basic (in shares) 26,660 25,514 26,479 24,940
Weighted average common shares outstanding –diluted (in shares) 26,660 25,514 26,479 24,940
Basic net income (loss) per common share (in dollars per share) $ 0.04 $ 0.11 $ (0.27) $ 0.05
Diluted net income (loss) per common share (in dollars per share) $ 0.04 $ 0.11 $ (0.27) $ 0.05
v3.24.3
Stock Incentive Plan - Shares Plan (Details)
May 02, 2024
shares
2024 Incentive Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares authorized (in shares) 1,150,000
v3.24.3
Stock Incentive Plan - Schedule of Nonvested Restricted Stock Activity (Details) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Stock-based awards:            
Vested (in shares)       (11)   0
Stock-based compensation expense       $ 7,400 $ 17,900  
Accelerated amortization of stock-based compensation     $ 11,800 $ 0 $ 11,799  
Restricted Common Stock            
Stock-based awards:            
Stock-based awards, beginning of period (in shares) 1,417 1,203 1,708 1,374 1,708 1,708
Granted (in shares) 195 171   339 361  
Vested (in shares) (51) 0   (152) (692)  
Forfeited (in shares) (1) 0   (1) (3)  
Stock-based awards, end of period (in shares) 1,560 1,374   1,560 1,374 1,374
Stock-based compensation expense $ 2,255 $ 1,898   $ 6,514 $ 17,936  
Stock in lieu of compensation            
Stock-based awards:            
Granted (in shares) 98 57   157 141  
Stock awards            
Stock-based awards:            
Granted (in shares) 97 114   182 220  
v3.24.3
Stock Incentive Plan - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Jun. 03, 2024
May 16, 2024
May 02, 2024
Jan. 12, 2024
Jan. 02, 2024
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jan. 01, 2024
2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Employee percentage of salary (in percent)                     100.00%
2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Employee percentage of salary (in percent)         50.00%            
Restricted Common Stock                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           195,000   171,000 339,000 361,000  
Restricted Common Stock | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period             8 years        
Restricted Common Stock | Employee                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period 5 years                    
Granted (in shares) 7,000     79,533              
Restricted Common Stock | Employee | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           195,447          
Restricted Common Stock | Nonemployee                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period   3 years 3 years 5 years              
Granted (in shares)   24,887 22,070 10,159              
Stock in lieu of compensation                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           98,000   57,000 157,000 141,000  
Stock in lieu of compensation | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)       43,292              
Stock in lieu of compensation | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           98,111          
Stock in lieu of compensation | Nonemployee                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)   15,553                  
Restricted period | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)       36,241              
Restricted period | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           97,336          
Restricted period | Nonemployee                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)   9,334                  
RSU | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)               0   0  
Performance period         3 years            
RSU | 2014 Incentive Plan | Executive Officer                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Performance period         3 years            
Fair value of shares granted         $ 2.6            
Weighted average grant date fair value (in dollar per share)         $ 19.24            
RSU | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           0          
Absolute TSR Units | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)               0   0  
Absolute TSR Units | 2014 Incentive Plan | Executive Officer                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Weighted average grant date fair value (in dollar per share)         13.67            
Absolute TSR Units | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           0          
Relative TSR Units | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)               0   0  
Relative TSR Units | 2014 Incentive Plan | Executive Officer                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Weighted average grant date fair value (in dollar per share)         20.77            
Relative TSR Units | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           0          
Time-Based TSR Units | 2014 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)               0   0  
Time-Based TSR Units | 2014 Incentive Plan | Executive Officer                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Weighted average grant date fair value (in dollar per share)         $ 26.62            
Time-Based TSR Units | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)           0          
Minimum | Restricted Common Stock | Employee                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period       3 years              
Minimum | Restricted Common Stock | Employee | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period           3 years          
Maximum | Restricted Common Stock | Employee                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period       8 years              
Maximum | Restricted Common Stock | Employee | 2024 Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Vesting period           8 years          
v3.24.3
Stock Incentive Plan - Schedule of Valuation Assumptions (Details) - Performance Based Restricted Stock Units - 2014 Incentive Plan
Jan. 02, 2024
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Volatility 25.00%
Dividend assumption 5.40%
Expected term 3 years
Risk-free rate 4.30%
Stock price (in dollars per share) $ 26.62
v3.24.3
Stock Incentive Plan - Schedule of RSU Activity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 01, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Amortization expense       $ 7,400 $ 17,900  
Vested RSUs (in shares)       11,000   0
RSU | 2014 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Stock-based awards, beginning of period (in shares)     0   0 0
Granted (in shares)     0   0  
Stock-based awards, end of period (in shares)     0   0  
Amortization expense     $ 0   $ 0  
Grant Date Value Remaining at period end to be Amortized During the Performance Period     $ 0   $ 0  
Vested RSUs (in shares)     0   0  
RSU | 2014 Incentive Plan | Share-Based Payment Arrangement, Tranche One            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Vesting percentage       33.00%    
RSU | 2014 Incentive Plan | Share-Based Payment Arrangement, Tranche Two            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Vesting percentage       33.00%    
RSU | 2014 Incentive Plan | Share-Based Payment Arrangement, Tranche Three            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Vesting percentage       33.00%    
RSU | 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Stock-based awards, beginning of period (in shares) 134,000 134,000        
Granted (in shares)   0        
Stock-based awards, end of period (in shares)   123,000   123,000    
Amortization expense   $ 242        
Grant Date Value Remaining at period end to be Amortized During the Performance Period   $ 1,694        
Vested RSUs (in shares)   11,000        
RSU | 2014 and 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Stock-based awards, beginning of period (in shares)       0    
Granted (in shares)       134,000    
Stock-based awards, end of period (in shares)   123,000   123,000   0
Amortization expense       $ 876    
Grant Date Value Remaining at period end to be Amortized During the Performance Period       $ 1,694    
Vested RSUs (in shares)       11,000    
Absolute TSR Units | 2014 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)     0   0  
Absolute TSR Units | 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)   0        
Absolute TSR Units | 2014 and 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)       57,000    
Relative TSR Units | 2014 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)     0   0  
Relative TSR Units | 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)   0        
Relative TSR Units | 2014 and 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)       43,000    
Time-Based TSR Units | 2014 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)     0   0  
Vested RSUs (in shares) 11,206          
Time-Based TSR Units | 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)   0        
Time-Based TSR Units | 2014 and 2024 Incentive Plan            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]            
Granted (in shares)       34,000    
v3.24.3
Other Assets, net - Schedule of Other Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Notes receivable, net of credit loss reserve $ 20,280 $ 30,775
Straight-line rent receivables, net 19,711 18,481
Fair value of interest rate swaps 10,492 16,417
Leasing commissions, net 3,920 2,312
Sales-type lessor receivable 3,017 3,028
Financing lease right-of-use assets 2,442 2,486
Prepaid assets 2,294 1,203
Accounts receivable, net 2,137 2,739
Above-market intangible assets, net 2,126 2,645
Interest receivable, net 1,798 1,906
Operating lease right of use assets 706 729
Deferred financing costs, net 312 471
Other 641 684
Other assets, net $ 69,876 $ 83,876
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets, net Other assets, net
v3.24.3
Other Assets, net - Additional Information (Details)
 2 Months Ended 9 Months Ended
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
hospital
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Geriatric Behavioral Hospital        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Number of properties used to secure notes by borrower | hospital   6    
Term Loan | Long-term Acute Care Hospitals        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Number of properties used to secure notes by borrower | hospital   7    
Term Loan | Inpatient Rehabilitation Hospitals        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Number of properties used to secure notes by borrower | hospital   1    
Notes receivable        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable interest rate   9.00%    
Non-cash interest rate   3.00%    
Receivable allowance     $ 1,400,000  
Notes receivable | Revolving Credit Facility        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable interest rate   9.00%    
Notes receivable | Revolving Credit Facility | Forecast        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Payment received $ 40,000      
Notes receivable | Geriatric Inpatient Behavioral Hospital        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Receivable allowance     $ 11,000,000  
Notes receivable | Term Loan        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   $ 3,800,000   $ 6,000,000
Payment received   $ 250,000    
Note receivable interest rate   9.00%    
Note Receivable 4 | Variable Interest Entity, Not Primary Beneficiary | Revolving Credit Facility        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   $ 6,300,000   5,400,000
Note Receivable 4 | Term Loan | Variable Interest Entity, Not Primary Beneficiary        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   17,000,000.0   17,000,000.0
Note receivable (revolving credit facility) | Unfunded Loan Commitment        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   $ 2,200,000    
Note receivable (revolving credit facility) | Revolving Credit Facility        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable interest rate   9.00%    
Non-cash interest rate   3.00%    
Note receivable (revolving credit facility) | Variable Interest Entity, Not Primary Beneficiary        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   $ 2,220,000   $ 2,300,000
Notes receivable (revolving credit facility and term loan), net of credit loss | Unfunded Loan Commitment        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   $ 2,000,000.0    
Note receivable (mortgage note)        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable interest rate   10.00%    
Note receivable (mortgage note) | Variable Interest Entity, Not Primary Beneficiary        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Note receivable   $ 2,000,000    
v3.24.3
Other Assets, net - Schedule of VIEs (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Variable Interest Entity [Line Items]    
Notes receivable, net of credit loss reserve $ 20,280 $ 30,775
Variable Interest Entity, Not Primary Beneficiary | Note receivable (term loan)    
Variable Interest Entity [Line Items]    
Note receivable 3,750  
Maximum exposure to loss 3,750  
Variable Interest Entity, Not Primary Beneficiary | Note receivable (revolving credit facility)    
Variable Interest Entity [Line Items]    
Note receivable 2,220 $ 2,300
Maximum exposure to loss 2,220  
Variable Interest Entity, Not Primary Beneficiary | Note receivable (mortgage note)    
Variable Interest Entity [Line Items]    
Note receivable 2,000  
Maximum exposure to loss 2,000  
Variable Interest Entity, Not Primary Beneficiary | Notes receivable (revolving credit facility and term loan), net of credit loss    
Variable Interest Entity [Line Items]    
Notes receivable, net of credit loss reserve 12,310  
Maximum exposure to loss $ 12,310  
v3.24.3
Other Liabilities, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Other Liabilities Disclosure [Abstract]    
Prepaid rent $ 5,880 $ 5,378
Security deposits 2,951 3,765
Below-market lease intangibles, net 2,593 3,188
Fair value of interest rate swaps 476 0
Financing lease liability 3,265 3,277
Operating lease liability 766 775
Other 558 485
Other liabilities, net $ 16,489 $ 16,868
Finance lease, liability, statement of financial position [Extensible Enumeration] Other liabilities, net Other liabilities, net
Operating lease, liability, statement of financial position Other liabilities, net Other liabilities, net
v3.24.3
Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Notes receivable, net of credit loss $ 20,280 $ 30,775
Interest rate swap asset 10,492 16,417
Interest rate swap liability 476 0
Carrying Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Notes receivable, net of credit loss 12,310 22,435
Mortgage note payable (principal amount) 0 4,821
Carrying Value | Notes receivable    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Notes and mortgage note receivable 7,970 8,340
Carrying Value | Interest rate swaps    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest rate swap asset 10,492 16,417
Interest rate swap liability 476 0
Fair Value | Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Notes receivable, net of credit loss   23,040
Mortgage note payable (principal amount) 0 4,791
Fair Value | Fair Value, Inputs, Level 2 | Notes receivable    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Notes and mortgage note receivable 7,835 8,159
Fair Value | Fair Value, Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Notes receivable, net of credit loss 12,310  
Fair Value | Interest rate swaps | Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest rate swap asset 10,492 16,417
Interest rate swap liability $ 476 $ 0
v3.24.3
Commitments and Contingencies (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
project
Tenant Improvements Allowances  
Other Commitments [Line Items]  
Commitment $ 26.0
Tenant Improvements, Redevelopment Projects  
Other Commitments [Line Items]  
Commitment $ 13.1
Number of projects | project 6
Capital Improvements  
Other Commitments [Line Items]  
Commitment $ 3.1
Capital Improvements, Redevelopment Projects  
Other Commitments [Line Items]  
Commitment $ 0.8
Number of projects | project 6
v3.24.3
Subsequent Events (Details) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 24, 2024
Oct. 16, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Subsequent Event [Line Items]            
Dividend declared (in dollars per share)     $ 0.4625 $ 0.4525 $ 1.3800 $ 1.3500
Revolving Credit Facility | Third Amended And Restated Credit Facility | Line of Credit            
Subsequent Event [Line Items]            
Maximum borrowing capacity     $ 150,000,000.0   $ 150,000,000.0  
Subsequent Event            
Subsequent Event [Line Items]            
Dividend declared (in dollars per share) $ 0.465          
Subsequent Event | Revolving Credit Facility | Third Amended And Restated Credit Facility | Line of Credit            
Subsequent Event [Line Items]            
Maximum borrowing capacity   $ 400,000,000        
Decrease in variable rate   0.10%        
Variable rate percentage   0.30%        
Subsequent Event | A-3 Term Loan, net | Third Amended And Restated Credit Facility | Term Loan            
Subsequent Event [Line Items]            
Repayment of debt amount   $ 75,000,000        
Commmunity Healthcare (NYSE:CHCT)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Commmunity Healthcare Charts.
Commmunity Healthcare (NYSE:CHCT)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Commmunity Healthcare Charts.